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ABSTRACT
Background. We investigate whether the urinary proteome
refines the diagnosis of renal dysfunction, which affects over
10% of the adult population.
Methods. We measured serum creatinine, estimated glomeru-
lar filtration rate (eGFR) and 24-h albuminuria in 797 people
randomly recruited from a population. We applied capillary
electrophoresis coupled with mass spectrometry to measure
multi-dimensional urinary proteomic classifiers developed for
renal dysfunction (CKD273) or left ventricular dysfunction
(HF1 and HF2). Renal function was followed up in 621 partici-
pants and the incidence of cardiovascular events in the whole
study population.
Results. In multivariable-adjusted cross-sectional analyses,
higher biomarker levels analysed separately or combined by
principal component analysis into a single factor (SF), corre-
lated (P ≤ 0.010) with worse renal function. Over 4.8 years,
higher HF1 and SF predicted (P ≤ 0.014) lowering of eGFR;
higher HF2 predicted (P ≤ 0.049) increase in serum creatin-
ine and decrease eGFR. HF1, HF2 and SF predicted pro-
gression from CKD Stages 2 or ≤2 to Stage ≥3, with risk
estimates for a 1-SD increment in the urinary biomarkers
ranging from 38 to 71% (P≤ 0.039). HF1, HF2 and SF yielded
a net reclassification improvement of 31–51% (P≤ 0.029). Over
6.1 years, 47 cardiovascular events occurred. HF2 and SF,
independent of baseline eGFR, 24-h albuminuria and other
covariables were significant predictors of cardiovascular compli-
cations with risk estimates for 1-SD increases ranging from 32
to 41% (P≤ 0.047).
Conclusions. The urinary proteome refines the diagnosis of
existing or progressing renal dysfunction and predicts cardio-
vascular complications.
Keywords: chronic kidney disease, eGFR, population science,
renal function, urinary proteomics
INTRODUCTION
Chronic kidney disease (CKD) is becoming a major health
problem affecting the quality of life of millions of people and
draining health care resources. In the USA, CKD defined as an
estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
increased from 10.0% in 1988–94 to 13.1% in 1999–2004 [1].
Furthermore, the Global Burden of Disease Study 2010 collab-
oration estimated that worldwide 0.403 million of nearly
50 million deaths occurring annually, were attributable to
CKD in 1990 and 0.736 in 2010, representing an increase by
82.3% [2]. Across all ages, over the same time span, the years
lived with CKD increased by 57.1% from 2.56 to 4.02 million
[3], while the disability-adjusted life years, a metric that cap-
tures both premature mortality and the prevalence of ill-health
increased by 51.7% from 13.9 to 21.2 million [4]. Diagnosis of
CKD before eGFR starts declining and prediction of CKD is
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irreversible renal dysfunction that often progresses to end-
stage renal failure and causes cardiovascular complications
and premature death [3, 4].
Recent publications proved the feasibility to develop
multi-dimensional classifiers based on the urinary proteome
that are associated with CKD [5, 6], and left ventricular dys-
function [7], but they were mainly derived in CKD patients
matched with controls [8–10] or in patient cohorts with dia-
betes [5] or CKD [6]. In the current study, we investigated the
performance of these biomarkers [5–7] in a general population.
We assessed their association cross-sectionally and longitudinal-
ly in relation to renal function, and prospectively in relation to
the incidence of cardiovascular complications.
MATERIALS AND MEHODS
Study population
The Ethics Committee of the University of Leuven approved
the Flemish Study on Environment, Genes and Health Out-
comes (FLEMENGHO) [11, 12]. Recruitment started in 1985
and continued until 2004. The initial participation rate was
78.0%. The participants were repeatedly followed up [11, 12].
From May 2005 to May 2010, we mailed an invitation letter to
1208 former participants for a follow-up examination. However,
153 were unavailable, because they had died (n = 26), had been
institutionalized or were too ill (n = 27), or because they had
moved out of the area (n = 100). Of the remaining 1055 former
participants, 828 renewed informed consent. The participation
rate was therefore 78.5%. We excluded 31 participants from the
cross-sectional analyses, because either no urine (n = 22) or no
blood sample (n = 9) was available. Thus, the number of partici-
pants statistically analysed totalled 797, of whom 621 (77.9%)
participated in the follow-up of renal function.
Assessment of renal function and biochemical variables
We measured the concentration of creatinine in serum,
using Jaffe’s method [13], with modifications described else-
where [14, 15], on automated analysers in a single-certified la-
boratory. We assessed renal function from serum creatinine,
eGFR computed by the Modification of Diet in Renal Disease
(MDRD) [16] and the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) [17] equations. CKD stages, defined
according to the National Kidney Foundation KDOQI guide-
line, were eGFR ≥90, 60–89, 45–59, 30–44, 15–29 and <15
mL/min/1.73 m2 for Stage 1, 2, 3A, 3B, 4 and 5, respectively
(http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_
class_g1.htm).
At baseline, we also measured blood glucose, serum total
and high-density (HDL) cholesterol, serum γ-glutamyltransfer-
ase as an index of alcohol intake, and micro-albumin in 24-h
urine collections. Diabetes mellitus was a self-reported diagno-
sis, a fasting glucose level of at least 126 mg/dL, or use of anti-
diabetic agents [18]. Micro-albuminuria was a 24-h urinary
excretion ranging from 30 to 300 mg and macro-albuminuria
a 24-h excretion exceeding 300 mg.
Proteomic classifiers
The Supplementary data (pages 2–4) gives detailed informa-
tion on the preparation and processing of urine samples. Peptide
fragments identified in previous studies [7, 8] were combined into
a single summary variable, using the support-vector machine-
based MosaCluster software, version 1.6.5. In the present study,
we used CKD273 as a multi-dimensional classifier based on 273
urinary peptide biomarkers that were significantly associated
with CKD [8]. We also assessed two multi-dimensional classi-
fiers associated with decreased left ventricular function and
based on 85 (HF1) [7] and 671 (HF2) urinary peptide frag-
ments. The peptide fragments included in CKD273 [8] have been
published. The Supplementary data provide information on the
peptide fragments making up HF1 (Supplementary data, Table S1)
and HF2 (Supplementary data, Table S2), the peptides with
known amino-acid sequence included in HF1 (Supplementary
data, Table S3) and HF2 (Supplementary data, Table S4), and
on the characteristics of 20 peptides shared by CKD273, HF1
and HF2 (Supplementary data, Table S5).
Other measurements
At the examination centre, nurses administered a question-
naire to collect detailed information on each participant’s
medical history, smoking and drinking habits and intake of
medications. The conventional blood pressure was the average
of five consecutive auscultatory readings obtained with the
subject in the seated position. The mean arterial pressure was
diastolic blood pressure plus one-third of the difference between
systolic and diastolic blood pressure. Hypertension was a blood
pressure of at least 140 mmHg systolic or 90 mmHg diastolic or
use of antihypertensive drugs. The body mass index was weight
in kilograms divided by the square of height in meters.
Ascertainment of events
Via the National Population Registry in Brussels, Belgium,
we ascertained vital status of all of the participants until 31 De-
cember 2012. We obtained the International Classification of
Disease codes for the immediate and underlying causes of
death from the Flemish Registry of Death Certificates. We also
collected information on the incidence of non-fatal events via
follow-up visits with repeat administration of the same stan-
dardized questionnaire.
Fatal and non-fatal cardiac events included myocardial in-
farction, acute coronary syndrome, new-onset angina (stable
or unstable), chronic ischaemic heart disease, coronary revas-
cularization, heart failure, new-onset atrial fibrillation and life-
threatening arrhythmias. Fatal and non-fatal cardiovascular
events comprised cardiac endpoints, stroke, transient ischae-
mic attack, aortic aneurysm, pulmonary heart disease, arterial
embolism, peripheral arterial disease and revascularization of
peripheral arteries. All events were adjudicated against the
medical records of general practitioners or hospitals.
Statistical analysis
For database management and statistical analysis, we used
the SAS system, version 9.3 (SAS Institute, Inc., Cary, NC,

























ANOVA and proportions by Fisher’s exact test. We computed
single correlation coefficients to assess unadjusted associations
between variables. We searched for covariables of the renal
function indices using a stepwise regression procedure with
the P-values for variables to enter and stay in the models set at
0.15. We combined the three urinary proteomic variables into
a single factor (SF), using the PROC FACTOR procedure im-
plemented in the SAS software package with the method set to
principal and rotation to varimax. Renal function and changes
in renal function were analyses as continuous or categorical
variables, using multivariable-adjusted linear regression, logis-
tic regression and Cox modelling, as appropriate. We used
Cox proportional hazard regression to model the incidence of
death and cardiovascular complications as function of the
baseline values of the proteomic biomarkers, renal function
and other covariables. Finally, we assessed the added capacity
of the urinary proteomic biomarkers to predict worsening of
renal function, using the integrated discrimination improve-
ment (IDI) and the net reclassification improvement (NRI)
[19, 20]. IDI is the difference between the discrimination
slopes of basic models and basic models extended with the
urinary biomarker of interest. The discrimination slope is the
difference in predicted probabilities (%) between cases and
controls. We calculated the continuous NRI as described by
Pencina et al. [21]. First, we predicted in each subject the
5-year risk for a worsening in renal dysfunction from a Cox
proportional hazards model with and without the biomarker
included. NRI is then calculated as 2 × [P(up|case)− P(up|
noncase)]. P(up|case) is the percentage of subjects with a
worsening in renal dysfunction, whose predicted probability is
increased by adding the biomarker to the model. Likewise,
P(up|noncase) is the percentage of subjects without a worsen-
ing in renal function, whose predicted probability is increased
by adding the biomarker.
RESULTS
Characteristics of participants
Age averaged 51.0 years (range 18–89 years) and the propor-
tion of women was 50.7%. Of 797 participants, 338 (42.4%) had
hypertension, of whom 207 (61.2%) were on antihypertensive
drug treatment, and 9 (1.1%) had diabetes. Among 207 patients
on treatment with antihypertensive drugs, 82 (39.6%) used diure-
tics, 168 (81.2%) used inhibitors of the renin system (β-blockers,
angiotensin-converting enzyme inhibitors or angiotensin recep-
tor blockers) and 40 (19.3%) were on treatment with vasodilators
(calcium channel blockers or α-blockers). Among treated patients
78 (37.7%) were on combination therapy with >1 drug class.
Table 1 lists the characteristics of participants by quartiles of
the distribution of CKD273. Age, body mass index, central
obesity, systolic and mean arterial blood pressure, the preva-
lence of hypertension and total cholesterol increased (P≤ 0.006)
with higher category of CKD273. Among all participants, 29
(3.6%) had micro-albuminuria and 3 (0.4%) had macro-albu-
minuria. Renal function as assessed by serum creatinine, eGFR
or 24-h urinary albumin excretion decreased (P < 0.0001) with
higher CKD273 category. The prevalence of micro-albuminuria
increased across the quartiles of the CKD273 distribution (P <
0.0001) with frequencies of 0.5% (n = 1), 1.5% (n = 3), 3.0%
(n = 6) and 9.6 (n = 19), respectively. Macro-albuminuria oc-
curred only in the top CKD273 quartile. The proportion of
women, smokers, consumers of alcohol, diabetic patients and
average heart rate did not differ (P≥ 0.20) across CKD273 cat-
egories. Supplementary data, Figure S1 displays the distributions
of the urinary proteomic markers. Figure 1 gives the distribu-
tions of the renal function indices at baseline and follow-up.
Combination of proteomic biomarkers into a SF
The correlations of CKD273 with HF1 and HF2 were 0.47
and 0.45 (P < 0.0001), while that between HF1 and HF2 was
0.76 (P < 0.0001). To avoid collinearity in models including
more than one biomarker, we derived an SF (eigenvalue, 2.13)
as a linear combination of CKD273, HF1 and HF2. SF had
high loadings on CKD273 (r = 0.73), HF1 (r = 0.90) and HF2
(r = 0.89).
Cross-sectional association of renal function with
urinary proteomic markers
Continuous measures of renal function. The covariables
identified by stepwise regression analysis are given in Supple-
mentary data, Table S6, page 5. With adjustments for these
covariables applied (Table 2), serum creatinine increased
with CKD273 and SF (P≤ 0.010), whereas eGFR decreased
with all four proteomic biomarkers (P≤ 0.010). The 24-h
urinary albumin excretion increased (P≤ 0.006) with all urinary
proteomic biomarkers. The effect sizes for 1-SD increment were
8.9% [95% confidence interval (CI): 6.5, 11.3] for CKD273, 3.4%
(95% CI: 0.97, 5.8) for HF1, 5.9% (95% CI: 3.4, 8.6) for HF2 and
7.7% (95% CI: 5.1, 10.4) for SF.
Categorical measures of renal function. Categories accord-
ing to eGFR derived from the MDRD formula [16], included
22.1% (n = 176) of participants for Stage 1, 70.0% for Stage 2
(n = 558), 6.9% for Stage 3A (n = 55), 0.9% for Stage 3B (n = 7)
and 0.1% (n = 1) for Stage 4. Categories according to eGFR
derived from the CKD-EPI formula [17], included 32.1% (n =
256) of participants for Stage 1, 59.5% (n = 474) for Stage 2,
6.8% (n = 54) for Stage 3A, 1.4% (n = 11) for Stage 3B and
0.2% (n = 2) for Stage 4.
Table 3 shows that irrespective of the eGFR formula
applied, all odds ratios reached significance (P≤ 0.05) for all
four urinary biomarkers for the risk of having a worse renal
function, comparing Stages 2, ≥2, or ≥3 with Stage 1 or com-
paring Stage ≥3 with Stage 2. Furthermore, the risk of having
a 24-h albuminuria of 30 mg or more increased (P≤ 0.019)
with higher scores of the four biomarkers. The odds ratios as-
sociated with a 1–SD increment of the biomarker were 3.63
(95% CI: 2.31, 5.72) for CKD273, 1.63 (95% CI: 1.08, 2.46) for


























Longitudinal association of renal function with urinary
proteomic predictors
Of 797 participants, 621 (77.9%) had their renal function
indices reassessed after a median interval of 4.8 years (5–95th
percentile interval: 3.7, 5.4).
Continuous measures of renal function. Over follow-up,
serum creatinine increased by 5.74 μmol/L (95% CI: 4.59,
6.88; P < 0.0001), whereas eGFR according to the MDRD and
CKD-EPI formulae decreased by 6.89 mL/min/1.73 m2 (95%
CI: 6.05, 7.74; P < 0.0001) and 7.68 mL/min/1.73 m2 (95% CI:
6.89, 8.47; P < 0.0001), respectively (Figure 1).
In multivariable-adjusted analyses of the changes in renal
function, we accounted for baseline renal function, follow-up
duration and other covariables (Table 4). In general, higher
scores of the urinary proteomic biomarkers with the exception
of CKD273, predicted worsening of renal function. HF1 and
SF predicted (P≤ 0.014) lowering of eGFR (MDRD and CKD-
EPI). Higher HF2 predicted (P≤ 0.049) an increase in serum
creatinine and a decrease eGFR (MDRD and CKD-EPI).
Categorical measures of renal function. Over follow-up
(Supplementary data, Table S7), eGFR according to the
MDRD formula remained at the same Stage in 458 (73.8%)
participants, moved up in 139 (22.4%) and moved down in 24
(3.9%). According to the CKD-EPI formula, these numbers
were 431 (69.4%), 167 (26.9%) and 23 (3.7%), respectively. No
participant proceeded to CKD Stage 5 or renal replacement
therapy.
In multivariable-adjusted Cox regression (Table 5), HF1,
HF2 and SF, but not CKD273 (P≥ 0.11) predicted progression
from CKD Stages 2 or ≤2 to Stage ≥3, irrespective of the formula
used to estimate eGFR, with risk estimates for a 1–SD increment
in the urinary biomarkers ranging from 38 to 71% (P≤ 0.039).
Figure 2 provides the multivariable-adjusted risk functions for
the progression of CKD from Stage ≤2 to ≥3.
Improvement of prognostic accuracy
For a decline in eGFR from Stage ≤ 2 to ≥ 3 based on the
MDRD formula, IDI reached significance (P≤ 0.032) for HF2
and SF (Table 6). By applying the CKD-EPI formula, IDI was
significant (P≤ 0.043) for HF1, HF2 and SF. Irrespective of
the formula applied, the NRI was significant (P≤ 0.029) for
HF1, HF2 and SF (Table 6).
Incidence of events
Among 797 participants who had their urinary proteome
measured at baseline, the median follow-up was 6.11 years (5–95th
percentile interval: 3.68, 7.36). Mortality included 8 cardiovas-
cular and 13 non-cardiovascular deaths, and 6 deaths from
Table 1. Baseline characteristics of 797 participants by fourths of the CKD273 distribution
Characteristic <−0.82 −0.82 to −0.61 −0.61 to −0.35 ≥−0.35 P-value
Number of subjects (%)
Women 100 (50.0) 99 (49.5) 103 (52.0) 102 (51.3) 0.96
Smokers 38 (19.0) 39 (19.5) 45 (22.7) 39 (19.6) 0.78
Drinking alcohol 140 (70.0) 138 (69.0) 140 (70.7) 135 (67.8) 0.93
Hypertension 57 (28.5) 90 (45.0)‡ 82 (41.4) 109 (54.8)† <0.0001
Antihypertensive treatment 35 (17.5) 46 (23.0) 46 (23.2) 80 (40.2)‡ <0.0001
Diabetes mellitus 1 (0.5) 3 (1.5) 2 (1.0) 3 (1.5) 0.80
Mean (SD) of characteristic
Age (years) 45.2 (14.8) 48.6 (15.7)* 51.0 (14.6) 59.4 (14.2)§ <0.0001
Body mass index (kg/m2) 26.3 (4.4) 25.7 (4.1) 26.4 (4.1) 27.5 (4.6)* 0.002
Waist-to-hip ratio 0.86 (0.09) 0.86 (0.08) 0.88 (0.08)† 0.89 (0.08) <0.0001
Office blood pressure (mmHg)
Systolic pressure 125.3 (15.1) 128.8 (17.3)* 129.7 (18.8) 133.8 (18.3)* <0.0001
Diastolic pressure 78.5 (10.3) 80.5 (10.4) 79.6 (8.5) 80.0 (9.0) 0.22
Mean arterial pressure 94.1 (11.1) 96.6 (11.1)* 96.3 (10.2) 97.9 (10.2) 0.0009
Heart rate (b.p.m.) 64.2 (9.4) 63.4 (9.5) 63.4 (9.8) 62.9 (10.5) 0.20
Biochemical data
Serum creatinine (μmol/L) 80.5 (13.9) 83.6 (14.4)* 83.8 (12.9) 88.1 (20.6)* <0.0001
eGFR (MDRD, mL/min/1.73 m2) 86.8 (19.0) 81.4 (14.7)† 79.5 (15.5) 73.5 (14.1)§ <0.0001
eGFR (CKD-EPI, mL/min/1.73 m2) 89.9 (17.9) 84.6 (15.9)† 82.2 (16.4) 74.6 (15.9)§ <0.0001
24-h albuminuria (mg) 5.0 (3.7, 6.5) 5.2 (3.7, 6.7) 6.1 (4.5, 7.5)† 8.2 (5.1, 8.8)‡ <0.0001
Total cholesterol (mmol/L) 5.12 (1.01) 5.19 (1.00) 5.37 (0.99) 5.34 (0.88) 0.006
HDL cholesterol (mmol/L) 1.41 (0.34) 1.44 (0.36) 1.43 (0.36) 1.41 (0.34) 0.008
Total-to-HDL cholesterol ratio 3.80 (1.05) 3.77 (1.02) 3.93 (1.07) 3.97 (0.99) 0.046
Blood glucose (mmol/L) 4.90 (0.73) 4.89 (0.50) 4.92 (0.90) 5.04 (0.93) 0.073
γ-Glutamyltransferase (units/L) 22 (15, 30) 21 (14, 32) 23 (16, 31) 26 (16, 37)* 0.019
eGFR, estimated glomerular filtration rate calculated according to the MDRD or CKD-EPI formulas, as described in references [16] and [17], respectively. Office blood pressure was the
average of five consecutive readings. Hypertension was an office blood pressure of ≥140 mmHg systolic, or ≥90 mmHg diastolic, or use of antihypertensive drugs. For 24-h albuminuria
and γ-glutamyltransferase, values are the geometric mean (inter-quartile range). Conversion factors: creatinine from μmol/L to mg/dL, multiply by 0.0113; cholesterol from mg/dL to
mmol/L, multiply by 0.0259.





























undocumented causes. None of the biomarkers predicted total
mortality (P≥ 0.65).
During the follow-up, 47 cardiovascular events occurred
including 29 cardiac events (6 cases of heart failure). As
shown in Supplementary data, Table S8, CKD273 did not
predict these outcomes with hazard ratios for a 1–SD in-
crease ranging from 1.14 to 1.23 (P ≥ 0.26). Of the three
other urinary proteomic biomarkers, HF1 was a weak pre-
dictor of all cardiovascular and cardiac events with hazard
ratios for a 1–SD increase ranging from 1.28 to 1.41 (0.049 ≤
P ≤ 0.074). HF2 and SF significantly (P ≤ 0.047) predicted
the composite cardiovascular endpoint, irrespective of
whether the model included baseline eGFR or 24-h albumin-
uria, or both. In fully adjusted models, including all
covariables and both eGFR and 24-h albuminuria, the
hazard ratios associated with a 1–SD increase were 1.40
(95% CI: 1.06, 1.89; P = 0.018) for HF2 and 1.32 (95% CI:
1.00, 1.74; P = 0.047) for SF.
DISCUSSION
To our knowledge, our current study is the first to assess the
association of CKD with urinary proteomic biomarkers in a
general population. The key findings can be summarized as
follows: (i) in cross-sectional analyses, continuous measures of
renal function and CKD stages correlated with CKD273, HF1,
HF2 and SF; (ii) HF2 and SF predicted the incidence of cardio-
vascular complications; (iii) HF1, HF2 and SF predicted the
changes of the renal function indices over time and progres-
sion of the CKD stage; (iv) optimized discrimination limits
improved IDI and NRI for predicting the progression of renal
dysfunction from the urinary proteomic biomarkers. NRI and
IDI provide complimentary information. Indeed, adding a
biomarker to a model might increase the predicted probability
in cases, which means an increase in NRI, but perhaps only to
a limited extend, as reflected by IDI.
Our current study moves beyond the available literature
data, which were obtained in CKD patients matched with con-
trols [8–10] or in patient cohorts with diabetes [5] or CKD
([6]). Good et al. derived CKD273 in a training database con-
sisting of 609 patients with biopsy-proven CKD and 379
healthy controls [8]. Analysis of the urinary proteome yielded
634 peptides with significantly different signal between cases
and controls. This set was subsequently reduced to 273 pep-
tides with known sequence frequency. Good et al. reproduced
in a blinded manner this biomarker pattern in an independent
test database including 110 CKD patients and 34 controls.
Upon unblinding, all controls and 94 patients with CKD were
correctly classified, resulting in a sensitivity of 85.5% (95% CI:
77.5, 91.4) and a specificity of 100% (95% CI: 89.6, 100.0) [8].
The CKD273 proteomic marker was further studied in
three prospective studies [5, 6, 9]. In a study of 44 patients
with type 2 diabetes progressing to micro- or macro-albumin-
uria and 44 matched controls, the multivariable-adjusted odds
ratio associated with CKD273 was 1.35 (95% CI: 1.02, 1.79)
[9]. CKD273 significantly (P = 0.002) improved IDI over and
beyond baseline urinary albumin excretion and eGFR [9]. In a
study of 53 CKD patients, CKD273 increased with worse CKD
stage and was linearly correlated with eGFR (r = –0.64; P < 0.001).
Over 3.6 years of follow-up, four patients were lost to follow-
up. The CKD273 score was >0.55 in all 15 patients who
reached an endpoint, either dialysis (n = 9) or died (n = 6) [6].
None of the patients with a baseline CKD273 score <0.55
experienced an endpoint [6].
Several issues should be highlighted when comparing our
current results with the published literature on CKD273 [5, 6, 8, 9].
First, findings in patients with advanced CKD or diabetes
cannot be readily generalized to unselected people as enrolled in
our population study. This might explain why in our present
study the renal function indices were correlated with CKD273 in
cross-sectional analyses, whereas in longitudinal analyses
F IGURE 1 : Distributions of the renal function indices at baseline

























CKD273 did not predict change in renal function or progression
across stages of eGFR. Second, the published literature focused
on CKD273 [5, 6, 8, 9]. However, CKD is a forerunner of heart
failure and decline of left ventricular performance leads to pre-
renal dysfunction [22, 23]. We therefore assessed two multi-di-
mensional classifiers associated with left ventricular dysfunc-
tion. Third, we combined CKD273, HF1 and HF2 into SF.
However, in longitudinal analyses, the biomarker combining
Table 3. Multivariable-adjusted associations of eGFR with urinary proteomic biomarkers
Biomarkers Stage 2 versus Stage 1 Stage ≥3 versus Stage 1 Stage ≥2 versus Stage 1 Stage ≥3 versus Stage 2
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
MDRD
CKD273 1.70 (1.37, 2.11)§ 2.98 (1.80, 4.94)§ 1.76 (1.42, 2.18)§ 1.46 (1.09, 1.95)*
HF1 1.23 (1.00, 1.53)* 1.80 (1.18, 2.75)† 1.26 (1.02, 1.56)* 1.34 (1.01, 1.79)*
HF2 1.38 (1.09, 1.73)† 2.26 (1.43, 3.59)‡ 1.42 (1.13, 1.79)† 1.36 (1.02, 1.80)*
SF 1.64 (1.28, 2.09)§ 2.88 (1.70, 4.87)§ 1.70 (1.33, 2.17)§ 1.46 (1.10, 1.93)†
CKD-EPI
CKD273 1.73 (1.41, 2.12)§ 4.07 (2.42, 6.82)§ 1.82 (1.49, 2.22)§ 1.54 (1.16, 2.05)†
HF1 1.28 (1.06, 1.56)* 2.29 (1.47, 3.54)‡ 1.32 (1.09, 1.60)† 1.35 (1.02, 1.77)*
HF2 1.50 (1.20, 1.86)‡ 2.91 (1.86, 4.55)§ 1.56 (1.26, 1.93)§ 1.49 (1.13, 1.96)†
SF 1.74 (1.38, 2.19)§ 3.97 (2.32, 6.78)§ 1.83 (1.46, 2.29)§ 1.53 (1.17, 2.01)†
eGFR, estimated glomerular filtration rate calculated according to the MDRD or CKD-EPI formulas, as described in references [16] and [17], respectively. Frequencies of the eGFR stages
according to the MDRD and CKD-EPI are given in the Results section. Odds ratios, given with 95% CI, express the risk associated with a 1–SD increase in the proteomic biomarkers. All
associations were adjusted for mean arterial pressure, waist-to-hip ratio, smoking, log γ-glutamyltransferase (index of alcohol intake), total-to-HDL cholesterol ratio, blood glucose, log
24-h albuminuria, and use of diuretics, vasodilators (calcium channel blockers and α-blockers) and inhibitors of the renin–angiotensin system (β-blockers, angiotensin-converting-





Table 4. Multivariable-adjusted association of renal function changes with baseline urinary proteomic biomarkers
Biomarker measured at baseline Serum Creatinine eGFR (MDRD) eGFR (CKD-EPI)
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
CKD273 0.07 (−1.14, 1.27) −0.34 (−1.09, 0.41) −0.27 (−1.05, 0.50)
HF1 0.96 (−0.23, 2.15) −1.02 (−1.75, −0.29)† −0.95 (−1.71, −0.20)*
HF2 1.25 (0.01, 2.49)* −1.34 (−2.09, −0.60)‡ −1.27 (−2.05, −0.50)†
SF 1.03 (−0.23, 2.29) −1.18 (−1.94, −0.43)† −1.11 (−1.90, −0.32)†
eGFR, estimated glomerular filtration rate calculated according to the MDRD or CKD-EPI formulas, as described in reference [16] and [17], respectively. Change in renal
function was computed as follow-up minus baseline value. Estimates given with 95% CI, express the change in renal function associated with a 1–SD increase in the
explanatory variables derived from the urinary proteome. SDs were 0.38 for CKD273; 0.91 for HF1; 0.59 for HF2; and 0.96 for SF. All associations were adjusted for baseline
renal function and log urinary albumin, log-transformed follow-up time, mean arterial pressure, waist-to-hip ratio, smoking, blood glucose, log γ-glutamyltransferase, and
total-to-HDL cholesterol ratio. Associations with changes in serum creatinine and creatinine clearance were additionally adjusted for sex, age and body mass index.





Table 2. Multivariable-adjusted associations of renal function with urinary proteomic biomarkers
Explanatory variables (SD) Serum creatinine eGFR (MDRD) eGFR (CKD-EPI)
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
CKD273 (0.39) 1.57 (0.57, 2.58)† −3.83 (−4.96, −2.69)§ −4.17 (−5.30, −3.04)§
HF1 (0.92) 0.86 (−0.16, 1.88) −1.56 (−2.75, −0.38)† −2.09 (−3.27, −0.90)‡
HF2 (0.62) 0.90 (−0.18, 1.99) −2.47 (−3.70, −1.24)§ −3.24 (−4.46, −2.02)§
SF (1.0) 1.43 (0.34, 2.52)* −3.26 (−4.49, −2.03)§ −3.96 (−5.18, −2.74)§
eGFR, estimated glomerular filtration rate calculated according to the MDRD or CKD-EPI formulae, as described in references [16] and [17], respectively. Estimates given with 95% CI,
express the difference in renal function associated with a 1–SD increase in the proteomic biomarkers. All associations were adjusted for mean arterial pressure, waist-to-hip ratio,
smoking, log γ-glutamyltransferase (index of alcohol intake), total-to-HDL cholesterol ratio, blood glucose, log 24-h albuminuria, and use of diuretics, vasodilators (calcium channel
blockers and α-blockers) and inhibitors of the renin–angiotensin system (β-blockers, angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers). The association with





























information from the three classifiers did not perform better
than HF1 and HF2. Fourth, we assessed the incidence of car-
diovascular and cardiac events in relation to the urinary prote-
omic biomarkers and noticed that HF2 and SF were significant
predictors of such events, over and beyond covariables includ-
ing baseline eGFR and 24-h urinary albuminuria.
Our current results reinforce the concept that dysfunction
of the kidney and the left ventricle often co-exist [22–24].
Haemodynamic and non-haemodynamic mechanisms under-
pin the two-way interaction between the kidney and the heart
[22, 23]. A decline in left ventricular systolic function and
cardiac output activates the sympathetic nervous system and
the renin–angiotensin system. The ensuing sodium and water
retention and expansion of the circulating volume, although
maintaining renal perfusion, increase afterload and can aggra-
vate left ventricular dysfunction [22–24]. Left ventricular dia-
stolic dysfunction with preserved ejection fraction may be
accompanied with higher pressure in the central venous
system [25], which in turn may increase renal intratubular
pressure and reduce ultrafiltation pressure, thereby reducing
glomerular filtration [26]. The drivers of the non-haemo-
dynamic cardiorenal connection are the renin–angiotensin
system, sympathetic nervous tone, inflammation and the
balance between nitric oxide and reactive oxygen species [22].
Our study did not directly address the interaction between
renal and left ventricular function, but might point to an
avenue worthy of further research in predominantly asymp-
tomatic people.
The present study must be interpreted within the context of
some potential limitations. First, we determined proteinuria
only at baseline and not at follow-up. However, in our view,
24-h albuminuria reflects microcirculatory organ damage
rather than renal function. At baseline, this measure of target
organ damage increased with all urinary proteomic biomar-
kers. In the Olmesartan for the Delay or Prevention of Micro-
albuminuria in Type 2 Diabetes trial, micro-albuminuria
developed in 8.2% of the patients in the olmesartan group and
in 9.8% in the placebo group [27]. The incidence of micro-
albuminuria in our population study was presumably only a
minor fraction of that observed in the high-risk ROADMAP
patients, so that it is unlikely that we missed important infor-
mation. Second, we lost 176 participants (22.1%) in the
follow-up study of renal function. However, at baseline partici-
pants followed up and those not reassessed had similar distri-
butions of female sex (49.9 versus 53.4%; P = 0.41), age (50.8
versus 51.8 years; P = 0.52) and previous cardiovascular
disease (4.8 versus 6.3%; P = 0.45). Third, the renal function
indices were only measured twice. However, Figure 1 shows
the expected age-related shift, which excludes confounding by
regression-to-the mean. Finally, CKD273 and HF1 shared 24
common peptide fragments, CKD273 and HF2 135 and HF1
and HF2 47. However, only 20 peptides were common to
F IGURE 2 : Five-year risk of progressing from CKD Stage ≤2 to
stage ≥3 in 621 participants. CKD stages were based on the MDRD
(A) or CKD-EPI (B) formula, as described in references [16] and
[17]. To plot risk functions simultaneously for four biomarkers, we
expressed the scores in units of standard deviation of the respective
distributions. The risks were adjusted for baseline values of mean ar-
terial pressure, waist-to-hip ratio, smoking, log γ-glutamyltransferase
(index of alcohol intake), total-to-HDL cholesterol ratio, blood
glucose and log 24-h albuminuria. P-values indicate the significance
of the 5-year risks associated with the urinary biomarkers.
Table 5. Multivariable-adjusted hazard ratios predicting changes in CKD stages in relation to the baseline urinary proteome
Endpoint Rate (%) Hazard ratios (95% CI)
CKD273 HF1 HF2 SF
MDRD
Stage 2→ ≥3 49/456 (10.7) 1.29 (0.94, 1.77) 1.39 (1.02, 1.89)* 1.57 (1.17, 2.11)† 1.52 (1.13, 2.05)†
Stage ≤2→ ≥3 50/579 (8.64) 1.30 (0.94, 1.78) 1.45 (1.06, 1.98)* 1.71 (1.29, 2.26)‡ 1.62 (1.21, 2.17)†
CKD-EPI
Stage 2→ ≥3 54/388 (13.9) 1.18 (0.87, 1.59) 1.38 (1.03, 1.84)* 1.41 (1.06, 1.88)* 1.41 (1.06, 1.88)*
Stage ≤2→ ≥3 54/580 (9.31) 1.33 (0.98, 1.81) 1.53 (1.13, 2.05)† 1.58 (1.20, 2.08)† 1.61 (1.22, 2.13)‡
eGFR, estimated glomerular filtration rate calculated according to the MDRD or CKD-EPI formulas, as described in reference [16] and [17], respectively. Frequencies of the eGFR stages
according to the MDRD and CKD-EPI are given in the Results section. Rate is the number of endpoints divided by number of participants at risk (%). Hazard ratios, given with 95% CI,
express the increase in risk associated with a 1–SD increase in the explanatory variables derived from the urinary proteome. SDs were 0.38 for CKD273; 0.91 for HF1; 0.59 for HF2; and
0.96 for SF. All hazard ratios were adjusted for baseline values of mean arterial pressure, waist-to-hip ratio, smoking, blood glucose, log γ-glutamyltransferase, total-to-HDL cholesterol





























CKD273, HF1 and HF2. Moreover, the signal strength of
shared polypeptides differed between classifiers, suggesting
that the classifiers provided complimentary rather than dupli-
cate diagnostic information. Supplementary data, Table S5 il-
lustrates the differences in signal intensity for 20 polypeptides
common to CKD273, HF1 and HF2.
CONCLUSION
The urinary proteome refines the diagnosis of already existing
or progressing renal dysfunction. Our current findings extend
previous reports including patients with CKD or diabetes mel-
litus [5, 6, 8, 9] to the general population, thereby providing a
proof of concept in people at low risk. However, further
studies are required to port our observation to clinical practice.
Prospective studies in other populations should confirm our
current findings and randomized clinical trials should demon-
strate that the urinary proteome changes in parallel with the
response to treatment. Having these research goals materia-
lized would be a major step forward in view of the high preva-
lence of CKD, which in several countries currently affects over
10% of the adult population [28, 29].
SUPPLEMENTARY MATERIAL
Supplementary data are available online at http://ndt.oxford-
journals.org.
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ABSTRACT
Background. Adiponectin plasma levels in chronic kidney
disease (CKD) are two to three times higher than in indivi-
duals with normal kidney function. Despite adiponectin’s
anti-diabetic, anti-inflammatory and anti-atherogenic proper-
ties, patients with CKD have insulin resistance, systemic in-
flammation and accelerated atherogenesis. Hence, although
adiponectin production is increased by adipose tissue in end-
stage renal disease (ESRD), it is unclear if its effects on metab-
olism remain intact.
Methods. To determine if there is adiponectin resistance in
ESRD, we measured tissue levels of adiponectin receptor-1
(AdipoR1) and adiponectin downstream effectors in ESRD
patients compared with normal kidney function controls.
Blood and tissue samples were obtained from participants at
the time of kidney transplantation or kidney donation. A
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Urinary proteomics  
Preparation and processing of the urine samples  
Participants collected 24–h urine samples within one week of the examinations. Using 24–h 
urine samples rather than spot urine samples minimizes the small influence of food intake 
during the day on the urinary proteome [3]. Aliquots were stored at –80 °C. Urine (0.7 mL) 
was thawed immediately before analysis and diluted with 0.7 mL of 2 M urea, 10 mM NH4OH 
containing 0.02% SDS [4]. To remove higher molecular mass proteins, such as albumin and 
immunoglobulin G, the sample was ultra-filtered using Centrisart ultracentrifugation devices 
(20 kDa MWCO; Sartorius, Göttingen, Germany) at 3,000 g relative centrifugal force until 1.1 
mL of filtrate was obtained. This filtrate was then applied onto a PD-10 desalting column (GE 
Healthcare, Uppsala, Sweden) equilibrated in 0.01% NH4OH in HPLC-grade H2O (Roth, 
Germany) to decrease matrix effects by removing urea, electrolytes, and salts, and to enrich 
polypeptides. Finally, all samples were lyophilized, stored at 4 ºC, and suspended in HPLC-
grade H2O shortly before CE-MS analyses [5].   
CE-MS analyses were performed using a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, Fullerton, USA) on-line coupled to a micrOTOF MS (Bruker Daltonic, 
Bremen, Germany) [5]. The ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was 
grounded, and the ion spray interface potential was set between -4 and -4.5 kV. Data 
acquisition and mass spectrometry acquisition methods were automatically controlled by the 
capillary electrophoresis via contact-close-relays. Spectra were accumulated every 3 s, over 
a range of charge states (m/z) 350 to 3000. Previous publications described the accuracy, 
precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS measurements in 
detail [6].   
Mass spectra were processed using MosaiquesVisu software, including peak picking, 
deconvolution and deisotoping [7]. Migration time and peak intensity were normalized using 
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internal polypeptide standards [8]. These fragments result from normal biological processes 
and appear to be unaffected by any disease state studied to date based on over 20000 
samples in the Mosaiques database [9]. The resulting peak list characterizes each 
polypeptide by its molecular mass, normalized capillary electrophoresis migration time, and 
normalized signal intensity. All detected polypeptides were deposited, matched, and 
annotated in a Microsoft SQL database, allowing further analysis and comparison of multiple 
patient groups.  
Proteomic classifiers  
Peptide fragments identified in previous studies were combined into a single summary 
variable, using the support-vector machine based MosaCluster software, version 1.6.5. In the 
present study, we used CKD273 as a multidimensional classifier based on 273 urinary 
peptide biomarkers that were significantly associated with CKD [10]. Application of the 
CKD273 classifier results in a classification score, reflecting the similarity to the CKD-specific 
pattern. In selected small cohorts, CKD273 enabled prognosis of diabetic nephropathy [11] 
or albuminuria [12] with accuracy superior to conventional predictors.   
Because CKD is a forerunner of heart failure and because heart failure leads to prerenal 
dysfunction [13,14], we also assessed to multidimensional classifiers associated with 
decreased left ventricular function. As published previously [15], HF1 combined information 
from 85 peptide fragments identified in 19 patients with diastolic left ventricular dysfunction 
and 19 controls. To generate the HF2 classifier, all urinary proteomic datasets from cases 
available in the Mosaiques database [9] were combined and compared with data from sex- 
and age-matched controls. Cases were 98 patients with left ventricular diastolic dysfunction 
recruited from our population [15] (n = 35) or admitted to the hospital because of overt heart 
failure (n = 63). The patients with overt heart failure were all on multiple drugs, included 
Page 4 of 54  
 
49.2% women. Mean age was 67.1 years. The underlying cause of heart failure was 
ischemic cardiomyopathy (50.8%), dilated cardiomyopathy (28.6%), hypertrophic 
cardiomyopathy (1.6%), valvular heart disease (1.6%) or unspecified (17.4%). Comparing 
cases with controls identified 710 potential biomarkers, based on a P-value of less than 0.05 
with adjustment for multiple testing applied. Using a take-one-out procedure [16] to remove 
potential biomarkers that are of no apparent value, the number of biomarkers was reduced to 
671. A MosaiquesVisu software based classifier including these 671 urinary peptides was 
developed, using all 196 (98 cases and 98 controls) datasets. Full information of the 
polypeptides making up the HF1 and HF2 classifiers (Tables S1 and S2) and on the 
polypeptides with known amino-acid sequence (Tables S3 and S4) is available in the 
supplementary data.  
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Identification of covariables of the renal function indices  
As shown in Table S6, serum creatinine increased with age (r2 = 0.014), mean arterial 
pressure (r2 = 0.005), the total-to-HDL serum cholesterol ratio (r2 = 0.017), urinary 
albuminuria (r2 = 0.021), and use of diuretics (r2 = 0.033). In contrast, serum creatinine was 
lower in women than men (r2 = 0.19), in smokers compared with non-smokers (r2 = 0.007), 
and decreased with central obesity (r2 = 0.005) and use of vasodilators (r2 = 0.008). The 
coefficient of multiple determination (R2) was 0.347.  
eGFR calculated by the MDRD formula [17] ( Table S6), was higher in smokers than non-
smokers (r2 = 0.005) and increased with -glutamyltransferase (r2  = 0.005). eGFR based on 
the MDRD formula decreased with mean arterial pressure (r2 = 0.035), the total-to-HDL 
serum cholesterol ratio (r2 = 0.008), urinary albuminuria (r2 = 0.018), and use of diuretics (r2 
= 0.022) and inhibitors of the renin system (r2 = 0.009). R2 was 0.146. Findings for the eGFR 
calculated according to the CKD-EPI formula ([18]) were similar. R2 was 0.224.   
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Table S1.   List of 85 polypeptides included in the HF1 biomarker   







% MA % MA R 
P-value 
(Unadjusted) 
81272 2211.98 33.23 0 0 0.42 2.67 0 1.99E-03 
129821 3333.36 19.42 0 0 0.47 2.39 0 8.72E-04 
8725 949.4 25.79 0.05 1.94 0.63 2.28 0.067 2.22E-04 
123106 3130.43 30.82 0.05 1.98 0.47 2.63 0.080 2.57E-03 
1577 840.41 23.17 0.05 1.65 0.47 1.85 0.095 3.29E-03 
103493 2658.22 19.5 0.05 3.36 0.47 3.29 0.109 4.71E-03 
44146 1518.6 19.37 0.11 1.91 0.58 2.49 0.145 1.33E-03 
4845 900.27 43.66 0.16 1.55 0.63 2.44 0.161 1.33E-03 
37610 1421.59 38.71 0.11 1.73 0.53 1.87 0.192 6.07E-03 
83441 2248.97 33.69 0.11 3.45 0.53 3.56 0.201 4.88E-03 
74703 2087.84 19.42 0.11 2.64 0.53 2.7 0.203 6.76E-03 
101157 2616.16 28.39 0.11 1.97 0.53 1.98 0.206 6.76E-03 
103022 2649.2 34.85 0.16 2.52 0.68 2.56 0.232 2.50E-03 
57360 1734.66 19.9 0.16 2.2 0.58 2.24 0.271 1.03E-02 
46091 1554.66 28.59 0.16 2.08 0.53 2.24 0.280 1.18E-02 
32022 1319.58 20.89 0.21 1.99 0.58 2.21 0.326 1.57E-02 
102269 2638.18 28.42 0.26 2.3 0.68 2.49 0.353 1.26E-02 
82708 2235.04 34.17 0.32 2.57 0.84 2.68 0.365 2.53E-03 
188895 11967.55 20.47 0.26 2.68 0.63 2.94 0.376 9.50E-03 
98089 2559.18 19.41 0.32 2.97 0.84 3 0.377 3.76E-03 
138143 3593.47 20.2 0.26 2.67 0.68 2.68 0.381 1.50E-02 
167786 4771.07 20.2 0.37 2.74 0.79 3.13 0.410 4.34E-03 
61984 1835.71 19.91 0.53 2.64 1 3.12 0.448 1.33E-04 
46369 1560.7 29.79 0.32 2.78 0.68 2.84 0.461 2.27E-02 
143947 3801.77 33.46 0.37 2.26 0.79 2.24 0.473 2.67E-02 
39275 1445.62 37.36 0.47 2.59 0.79 2.96 0.521 4.87E-03 
56493 1716.66 20.18 0.47 2.56 0.79 2.74 0.556 2.11E-02 
41972 1478.61 39.3 0.53 2.75 0.84 2.95 0.588 3.16E-03 
24168 1195.48 37.51 0.58 2.8 0.84 3.26 0.593 3.12E-03 
107858 2751.34 29.23 0.63 2.36 0.89 2.69 0.621 3.00E-03 
23356 1179.52 37.49 0.58 2.63 0.84 2.9 0.626 2.67E-02 
97599 2547.99 21.44 0.58 2.59 0.89 2.66 0.635 3.15E-02 
8695 949.22 34.33 0.53 2.46 0.68 3.01 0.637 2.78E-02 
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% MA % MA R 
P-value 
(Unadjusted) 
23697 1186.53 22.39 0.68 2.8 1 2.88 0.661 2.08E-02 
36566 1401.38 36.56 0.58 2.77 0.74 3.27 0.664 8.74E-03 
153832 4196.75 20.84 0.68 2.41 0.95 2.59 0.666 4.93E-03 
26670 1235.56 26.65 0.63 3.02 0.84 3.3 0.686 1.08E-02 
58050 1749.81 30.61 0.63 2.57 0.84 2.79 0.691 3.04E-02 
28005 1255.48 35.77 0.68 3.08 0.84 3.4 0.733 3.19E-02 
159396 4409.89 20 0.74 2.72 0.84 3.23 0.742 2.68E-02 
69979 1996.79 20.98 0.79 2.86 0.95 3.17 0.750 8.53E-03 
40737 1462.62 39.42 0.84 3.33 1 3.68 0.760 2.62E-04 
65368 1901.82 43.83 0.79 3.17 0.89 3.61 0.779 1.52E-02 
128086 3286.55 30.92 0.79 3.13 0.89 3.51 0.792 6.91E-04 
73434 2067.82 20.62 0.84 3.1 1 3.28 0.794 1.42E-02 
148086 3986.65 20.6 0.84 3.53 0.95 3.82 0.817 2.75E-03 
108574 2764.21 42.63 0.79 3.56 0.89 3.85 0.821 2.43E-02 
90344 2377.1 20.8 0.89 3.12 0.95 3.46 0.845 1.95E-02 
36759 1405.61 39.04 0.89 2.94 0.95 3.18 0.866 1.02E-02 
147541 3968.6 21.09 0.89 3.14 0.89 3.57 0.880 1.77E-03 
28561 1265.59 27.09 0.89 3.36 0.89 3.79 0.887 1.10E-02 
107460 2742.25 28.98 0.95 2.91 1 3.11 0.889 1.19E-02 
32171 1321.59 28.37 0.95 4.07 1 4.27 0.906 1.82E-02 
39322 1446.64 39.43 1 3.2 1 3.49 0.917 3.19E-02 
35339 1378.61 28.82 1 3.36 1 3.53 0.952 1.54E-02 
81196 2210.95 33.61 1 3.72 1 3.59 1.036 2.15E-02 
41601 1469.67 23.69 1 3.72 1 3.56 1.045 2.33E-02 
62866 1854.81 40.92 1 3.89 1 3.71 1.048 1.98E-02 
99021 2570.19 42.56 1 3.88 1 3.7 1.049 1.19E-02 
79136 2175 33.28 1 3.74 1 3.49 1.072 1.09E-02 
50840 1623.73 24.12 0.95 4.17 0.95 3.86 1.080 9.77E-03 
72533 2046.92 32.58 0.95 3.49 0.95 3.21 1.087 1.06E-02 
57537 1737.78 23.73 1 4.02 0.95 3.82 1.108 2.15E-02 
50212 1613.82 23.99 0.89 2.7 0.89 2.43 1.111 3.30E-02 
60149 1794.8 23.92 1 3.72 0.95 3.47 1.128 6.20E-03 
103198 2654.19 23.92 0.89 2.94 0.89 2.47 1.190 5.52E-03 
104786 2679.2 23.53 1 3.58 0.89 3.34 1.204 7.89E-03 
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% MA % MA R 
P-value 
(Unadjusted) 
33135 1338.6 23.99 1 2.86 0.89 2.65 1.213 1.20E-02 
73291 2064.92 24.46 0.84 2.75 0.79 2.37 1.234 3.25E-02 
45021 1532.62 26.35 1 2.82 0.89 2.55 1.243 1.67E-02 
99475 2577.25 24.67 0.95 2.78 0.89 2.38 1.247 6.05E-03 
40294 1452.66 23.61 1 2.85 0.84 2.62 1.295 2.17E-03 
35424 1380.64 23.83 0.95 2.79 0.79 2.56 1.311 7.17E-03 
131294 3375.57 31.92 1 2.87 0.79 2.71 1.341 1.80E-02 
111564 2841.26 24.54 0.89 3.21 0.79 2.67 1.354 4.98E-03 
104195 2663.2 23.51 0.89 2.61 0.74 2.29 1.371 2.07E-02 
28747 1268.57 27.25 1 3.44 0.74 3.32 1.400 1.01E-02 
44802 1526.69 23.92 0.79 2.51 0.63 2.1 1.499 1.10E-02 
113452 2889.35 24.08 0.89 2.47 0.58 2.29 1.655 7.34E-03 
69681 1989.88 32.44 0.84 2.43 0.42 2.51 1.936 2.03E-02 
55516 1696.72 23.95 0.79 2.54 0.42 2.39 1.999 1.59E-02 
80360 2196.02 33.16 0.68 2.74 0.26 2.73 2.625 1.15E-02 
82784 2236.98 27.14 0.63 2.28 0.21 2.31 2.961 1.29E-02 
56806 1723.52 37.74 0.53 2.31 0.11 2.52 4.417 1.03E-02 
129182 3320.51 24.25 0.47 2.07 0.05 2.1 9.266 4.71E-03 
ID, polypeptide identifier (SQL number); %, percentage of samples, in which the polypeptide could be detected; MA, mean signal 
amplitude of the polypeptides. R was calculated as ∑ (ln signal amplitude x frequency/number of participants) in controls divided by ∑ 
(ln signal amplitude x frequency/number of participants) in cases. The polypeptides were ordered by ascending R.   
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Table S2.   List of 671 polypeptides included in the HF2 biomarker   
ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
5675 911.43 25.88 0.29 266.81 0.85 709.73 0.38 0 
17968 1099.49 28.24 0.62 310.36 0.91 888.01 0.35 8.88178E-16 
14906 1050.48 26.92 0.37 238.08 0.82 738.97 0.32 1.9984E-15 
73434 2067.82 20.62 0.51 1158.94 0.93 2053.5 0.56 1.4877E-14 
78073 2156.97 22.22 0.45 904.53 0.88 1576.04 0.57 1.12577E-13 
69979 1996.79 20.98 0.39 720.87 0.86 1396.18 0.52 1.46772E-13 
23697 1186.53 22.39 0.45 536.63 0.89 884.15 0.61 7.46292E-13 
2659 860.36 26.14 0.26 194.46 0.71 568.02 0.34 1.86806E-12 
67263 1934.79 19.94 0.27 474.89 0.74 916.03 0.52 2.22089E-12 
30575 1297.58 27.36 0.33 1425.18 0.85 1526.54 0.93 4.74443E-12 
61984 1835.71 19.91 0.43 884.19 0.85 1510 0.59 9.06009E-12 
72641 2048.93 24.46 0.98 4334.17 0.96 1332.88 3.25 9.11588E-12 
28561 1265.59 27.09 0.49 2855.06 0.81 7418.24 0.38 1.11318E-11 
11413 981.59 24.8 0.49 401.63 0.85 1006.41 0.40 1.70459E-11 
49958 1608.73 30.93 0.34 578.89 0.85 739.65 0.78 2.41796E-11 
7408 935.45 23.68 0.05 36.97 0.46 169.15 0.22 2.43741E-11 
2505 858.39 23.24 0.34 191.41 0.76 383.25 0.50 4.6019E-11 
23518 1182.55 28.27 0.12 62.68 0.55 136.09 0.46 4.82525E-11 
35339 1378.61 28.82 0.95 2232.32 1 3398.04 0.66 4.97484E-11 
72343 2042.07 25.14 0.43 10352.8 0.03 1273.44 8.13 6.103E-11 
56493 1716.66 20.18 0.24 416.31 0.7 672.93 0.62 7.75853E-11 
17694 1096.48 26.08 0.67 3573.1 0.94 5547.8 0.64 1.67514E-10 
28466 1263.54 22.73 0.37 604.76 0.83 626.22 0.97 1.70054E-10 
51916 1636.7 20.03 0.43 1031.8 0.84 1378.19 0.75 1.90195E-10 
87692 2327.91 21 0.15 273.02 0.58 355.4 0.77 2.80282E-10 
60352 1798.72 36.95 0.1 131.41 0.5 280.84 0.47 3.49119E-10 
124909 3194.42 30.4 0.55 746 0.17 292.65 2.55 9.42768E-10 
115312 2939.15 33.77 0.17 203.53 0.57 283.48 0.72 1.08754E-09 
43543 1508.68 29.33 0.59 1979.23 0.93 2945.44 0.67 1.57317E-09 
32470 1326.55 29.2 0.35 218.46 0.72 362.3 0.60 1.67426E-09 
42404 1487.65 29.62 0.38 336.54 0.75 655.59 0.51 1.99523E-09 
46184 1556.74 40.03 0.1 154.65 0.48 400.39 0.39 2.88512E-09 
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ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
30699 1299.58 22.38 0.39 428.35 0.84 409.15 1.05 3.0367E-09 
16773 1080.48 27.77 0.09 89 0.46 194.48 0.46 3.05367E-09 
19828 1129.46 27.91 0.35 149.33 0.69 321.85 0.46 3.64891E-09 
28132 1257.64 19.92 0.42 1104.88 0.06 529.33 2.09 5.52722E-09 
84164 2257.87 35.93 0.18 437.59 0.57 1175.56 0.37 6.19304E-09 
15216 1058.48 24.89 0.49 1000.53 0.13 477.43 2.10 6.55992E-09 
147541 3968.6 21.09 0.63 1479.55 0.85 2807.96 0.53 7.13959E-09 
13342 1016.45 25.79 0.87 866.5 0.97 1808.79 0.48 1.1465E-08 
57531 1737.78 31 0.84 1573.88 0.94 2870.95 0.55 1.19037E-08 
66161 1916.77 20.32 0.5 1353.17 0.82 2464.52 0.55 1.34118E-08 
18943 1114.49 25.55 0.82 2185.57 0.93 4029.69 0.54 1.36723E-08 
90840 2389.24 22.4 0.43 11705.46 0.08 506.56 23.11 1.48139E-08 
33812 1352.56 29.77 0.23 217.57 0.63 234.65 0.93 1.71495E-08 
85020 2276.02 27.23 0.46 2506.77 0.81 3634.07 0.69 1.72695E-08 
48751 1592.7 22.18 0.37 1093.01 0.83 577.9 1.89 1.8047E-08 
77763 2149.96 27.76 0.97 3399.7 0.98 1724.29 1.97 2.02281E-08 
121716 3091.44 28.4 0.44 486.01 0.76 666.07 0.73 2.11918E-08 
73291 2064.92 24.46 0.86 1417.64 0.73 416.98 3.40 2.43001E-08 
41434 1466.65 28.52 0.35 426.47 0.72 472.77 0.90 2.62457E-08 
63812 1874.83 30.82 0.08 197.69 0.43 200.85 0.98 2.67978E-08 
97599 2547.99 21.44 0.38 405.88 0.72 558.72 0.73 2.69885E-08 
64054 1878.79 20.72 0.39 773.63 0.81 677.75 1.14 2.89355E-08 
125749 3223.31 21.61 0.18 290.75 0.55 402.35 0.72 3.91738E-08 
34009 1354.61 35.71 0.34 334.66 0.03 308.86 1.08 5.4766E-08 
138067 3590.7 29 0.07 114.33 0.4 279.39 0.41 5.60047E-08 
60628 1806.83 23.06 0.34 361 0.78 295.44 1.22 6.03294E-08 
15561 1065.5 25.45 0.04 61.89 0.34 164.52 0.38 6.25753E-08 
99808 2584.23 35.18 0.67 449.89 0.9 700.47 0.64 6.39811E-08 
82708 2235.04 34.17 0.5 396.97 0.78 760.84 0.52 7.40293E-08 
31480 1312.55 29.77 0.89 1505.39 0.95 2228.44 0.68 1.04546E-07 
107198 2736.4 21.3 0.31 15025.57 0.02 2343.04 6.41 1.08135E-07 
123969 3158.44 29.71 0.86 1809.86 0.74 981.31 1.84 1.23125E-07 
106195 2716.36 20.19 0.34 14019.79 0.04 718.01 19.53 1.2609E-07 
57360 1734.66 19.9 0.1 227.95 0.44 329.02 0.69 1.29332E-07 
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ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
25294 1215.43 27.59 0.1 295.73 0.42 748.62 0.40 1.33132E-07 
61711 1828.85 21.2 0.56 877.35 0.28 212.55 4.13 1.3589E-07 
19284 1121.49 27.68 0.05 270.31 0.35 255.97 1.06 1.36075E-07 
63209 1860.83 21.4 0.44 1458.34 0.9 1119.04 1.30 1.36324E-07 
56662 1720.69 19.67 0.11 193.27 0.44 352.82 0.55 1.59569E-07 
107460 2742.25 28.98 0.86 919.94 0.96 1398.45 0.66 1.83175E-07 
14478 1040.47 25.05 0.36 300.27 0.74 286.94 1.05 1.90817E-07 
46338 1560.58 21.77 0.31 567.01 0.68 659.38 0.86 2.07678E-07 
23409 1180.52 35.7 0.23 309.68 0.58 602.16 0.51 2.1728E-07 
1577 840.41 23.17 0.15 107.18 0.5 205.69 0.52 2.38837E-07 
88282 2339 34.01 0.56 594.88 0.84 846.66 0.70 3.18353E-07 
118224 3013.29 22.29 0.64 4554.03 0.91 7727.54 0.59 3.19188E-07 
58084 1750.78 23.83 0.58 950.75 0.9 1120.91 0.85 3.27827E-07 
153832 4196.75 20.84 0.38 264.09 0.7 415 0.64 3.3455E-07 
18988 1115.5 21.57 0.07 422.96 0.39 340.14 1.24 3.6776E-07 
72533 2046.92 32.58 0.94 3157.59 0.91 1786.23 1.77 3.89387E-07 
37340 1415.64 23.55 0.34 250.8 0.05 172.78 1.45 4.33972E-07 
29685 1283.55 27.27 0.17 174.58 0.5 235.3 0.74 4.75252E-07 
74703 2087.84 19.42 0.1 318.89 0.42 493.74 0.65 4.77952E-07 
43863 1513.63 29.51 0.03 190.62 0.3 158.41 1.20 4.91617E-07 
56884 1725.59 38.32 0.9 1923.19 1 3094.58 0.62 5.3905E-07 
119660 3044.42 34.29 0.05 54.27 0.32 311.66 0.17 5.47446E-07 
177848 6211.74 20.29 0.2 438.96 0.53 666.34 0.66 5.48173E-07 
61221 1817.69 20.23 0.77 3207.87 0.97 4826.24 0.66 5.48282E-07 
91342 2403.19 24.94 0.45 333.4 0.15 222.75 1.50 5.57645E-07 
64170 1880.9 43.91 0.3 476.28 0.6 1066.06 0.45 5.73076E-07 
104954 2682.14 22.49 0.81 926.16 0.99 1228.01 0.75 5.88132E-07 
70485 2009.88 32.29 0.77 801.64 0.55 434.86 1.84 5.98055E-07 
90344 2377.1 20.8 0.68 1380.11 0.93 2542.67 0.54 6.43034E-07 
73015 2059 33.08 0.51 433.53 0.23 90.09 4.81 6.5827E-07 
89083 2352.05 26.75 0.6 768.28 0.34 266.61 2.88 6.84124E-07 
20862 1143.52 36.97 0.31 168.72 0.6 380.82 0.44 7.42932E-07 
50904 1624.55 37.73 0.86 1193.34 0.99 1743.58 0.68 7.47011E-07 
76636 2124.84 20.37 0.07 212.77 0.36 248.44 0.86 7.89066E-07 
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ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
156081 4289.93 28.78 0.46 2355 0.74 3896.07 0.60 8.44141E-07 
80306 2194.97 20.17 0.17 374.8 0.5 495.49 0.76 8.77308E-07 
36769 1405.64 20.14 0.19 290.39 0.52 365.14 0.80 9.33202E-07 
8503 947.47 24.74 0.19 140.61 0.48 327.52 0.43 9.48105E-07 
99475 2577.25 24.67 0.87 691.24 0.9 332.35 2.08 9.55869E-07 
89900 2368.04 26.75 0.65 507.61 0.45 162.4 3.13 9.71083E-07 
73913 2076.95 21.78 0.27 649.6 0.6 1056.5 0.61 1.02976E-06 
80829 2203.64 35.26 0.04 61.06 0.3 110.5 0.55 1.09123E-06 
148557 4002.62 20.66 0.36 655.77 0.65 1304.21 0.50 1.09596E-06 
87365 2320.07 20.73 0.09 185.88 0.39 263.28 0.71 1.25682E-06 
49948 1608.68 22.35 0.3 427.86 0.73 248.88 1.72 1.28713E-06 
104786 2679.2 23.53 0.97 3608.38 0.91 2259.68 1.60 1.35314E-06 
144635 3831.81 28.48 0.33 585.57 0.66 1075.25 0.54 1.46424E-06 
129821 3333.36 19.42 0.05 497.52 0.33 265.9 1.87 1.56159E-06 
33973 1353.66 25.63 0.68 312.44 0.89 463.05 0.67 1.57151E-06 
116812 2977.18 19.52 0.35 759.33 0.72 687.85 1.10 1.67034E-06 
67632 1943.01 24.94 0.32 13045.5 0.05 4808.08 2.71 1.69836E-06 
101839 2628.22 34.97 0.86 1078.45 0.73 573.03 1.88 0.000001759 
110913 2823.33 29.12 0.5 386.13 0.75 629.26 0.61 1.82329E-06 
114702 2923.43 36.92 0.26 171.24 0.57 254.69 0.67 1.92617E-06 
23724 1187.36 35.69 0.48 1351.07 0.82 1360.67 0.99 1.92706E-06 
22725 1171.51 29.18 0.17 65.32 0.46 149.11 0.44 1.92858E-06 
101157 2616.16 28.39 0.09 120.1 0.4 95.3 1.26 1.94913E-06 
134635 3478.43 41.74 0.23 498.11 0.52 828.56 0.60 1.9993E-06 
32823 1332.54 21.74 0.43 1306.32 0.15 574.88 2.27 2.04622E-06 
124193 3166.27 22.06 0.44 674.01 0.71 1136.6 0.59 2.13141E-06 
17045 1085.42 20.77 0.1 333.94 0.38 1369.33 0.24 2.1539E-06 
60751 1807.81 20.65 0.86 2286.7 0.97 3288.38 0.70 2.19769E-06 
120423 3064.32 20.57 0.28 453.18 0.56 815 0.56 2.21835E-06 
42378 1486.68 21.15 0.37 317.84 0.7 433.68 0.73 2.27212E-06 
118597 3021.35 23.42 0.78 1741.99 0.95 2083.36 0.84 2.82992E-06 
55143 1692.8 30.89 0.43 586.61 0.7 907.46 0.65 2.93441E-06 
150781 4078.81 33.14 0.61 430.13 0.41 153.97 2.79 3.00875E-06 
44146 1518.6 19.37 0.16 301.07 0.47 429.11 0.70 3.0478E-06 
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ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
16059 1071.49 21.43 0.24 168.13 0.56 171.56 0.98 3.0793E-06 
64431 1885.65 38.82 0.31 305.69 0.69 250.54 1.22 3.12346E-06 
70456 2008.9 32.29 0.16 498.15 0.47 654.13 0.76 3.33657E-06 
73010 2058.94 23.15 0.4 284.87 0.71 324.45 0.88 3.4391E-06 
71943 2034.88 19.52 0.09 178.68 0.36 388.45 0.46 3.45045E-06 
67723 1945.88 41.9 0.33 815.93 0.07 219.59 3.72 3.66996E-06 
44679 1524.65 20.03 0.58 696.74 0.9 822.72 0.85 3.71683E-06 
12998 1009.45 27.27 0.14 130.04 0.44 195.64 0.66 3.82016E-06 
38011 1426.64 22.42 0.09 184.4 0.36 193.02 0.96 3.94795E-06 
38586 1435.51 19.75 0.08 157.25 0.34 273.26 0.58 3.96342E-06 
122400 3108.45 31.28 0.64 266.08 0.86 354.59 0.75 4.06715E-06 
24660 1203.57 26.76 0.13 77.91 0.41 159.05 0.49 4.17671E-06 
58880 1764.68 19.91 0.23 354.57 0.54 558.35 0.64 4.46484E-06 
105352 2695.2 23.52 0.97 5094.04 0.96 3271.88 1.56 4.55032E-06 
77018 2133.96 27.77 0.96 5570.45 0.95 2768.02 2.01 4.8937E-06 
128435 3295.53 25.45 0.24 163.97 0.53 343.3 0.48 5.13197E-06 
13145 1012.5 35.03 0.12 66.64 0.39 161.15 0.41 5.30167E-06 
132057 3401.66 23.49 0.4 866.82 0.67 1219.88 0.71 5.4511E-06 
52769 1649.73 22.64 0.7 886.2 0.88 1103.43 0.80 5.64197E-06 
122216 3106.19 19.58 0.08 400.63 0.36 297.86 1.35 5.81026E-06 
23224 1178.39 20.71 0.26 428.98 0.56 423.64 1.01 5.93879E-06 
137922 3583.64 41.47 0.23 423.34 0.56 527.89 0.80 6.2693E-06 
98596 2563.15 21.21 0.64 1170.12 0.89 1512.92 0.77 6.29775E-06 
74187 2080.94 20.2 0.42 809.32 0.71 1202.1 0.67 6.65843E-06 
58050 1749.81 30.61 0.45 409.94 0.74 505.2 0.81 7.01523E-06 
19773 1128.39 33.59 0.78 1391.02 0.83 2748.43 0.51 7.33822E-06 
38780 1438.66 30.2 0.21 431.04 0.54 421.44 1.02 7.56112E-06 
46091 1554.66 28.59 0.18 150.82 0.51 126.48 1.19 7.81906E-06 
148717 4008.81 23.42 0.4 9006.94 0.13 272.16 33.09 7.91402E-06 
80012 2191.99 22.39 0.45 641.13 0.74 794.69 0.81 8.44825E-06 
150441 4062.8 33.14 0.6 774.68 0.43 260.94 2.97 8.47916E-06 
158341 4368.9 20.21 0.24 1384.93 0.56 1531.99 0.90 8.97593E-06 
59773 1783.79 39.82 0.33 291.61 0.63 356.09 0.82 9.16298E-06 
59295 1773.82 34.6 0.31 111.58 0.6 184.11 0.61 9.19093E-06 
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(Da)  
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(min)  
%  MA  %  MA  
72896 2055.94 25.44 0.92 1350.02 0.96 814.06 1.66 9.81315E-06 
143652 3788.82 25.19 0.22 163.71 0.52 248.58 0.66 1.00722E-05 
49243 1593.69 22.38 0.16 573.04 0.48 278.35 2.06 1.01356E-05 
141007 3696.76 26.94 0.11 184.21 0.39 260.09 0.71 1.0196E-05 
151244 4097.87 24.61 0.62 747.28 0.81 1311.78 0.57 1.02206E-05 
65593 1907.77 23.78 0.1 98.62 0.38 109.12 0.90 1.08821E-05 
134053 3462.35 19.37 0.1 383.4 0.38 415.89 0.92 1.08821E-05 
56514 1716.77 28 0.62 473.76 0.88 667.19 0.71 1.16213E-05 
76090 2109.96 21.09 0.12 177.85 0.41 166.73 1.07 1.19602E-05 
39064 1442.63 27.63 0.55 530.59 0.32 213.77 2.48 1.19912E-05 
155132 4251.98 28.77 0.53 337.4 0.69 749.7 0.45 1.21296E-05 
117823 3002.24 23.8 0.19 130.66 0.51 115.1 1.14 1.27561E-05 
35204 1375.6 23.25 0.23 206.36 0.57 182.85 1.13 1.29376E-05 
91542 2407.09 27.67 0.68 463.41 0.92 572.79 0.81 1.36818E-05 
36868 1407.66 37.23 0.34 201.51 0.6 348.48 0.58 1.38609E-05 
125103 3202.43 30.6 0.16 159.05 0.44 208.66 0.76 1.392E-05 
42866 1496.68 30.37 0.23 299.77 0.57 229.35 1.31 1.41857E-05 
14047 1032.45 25.9 0.44 136.42 0.66 268.23 0.51 1.43904E-05 
37903 1424.66 39.3 0.86 1563.29 0.98 2260.54 0.69 1.49198E-05 
49122 1592.73 19.52 0.27 334.6 0.57 437.92 0.76 1.59179E-05 
63135 1859.8 31.39 0.18 299.62 0.47 403 0.74 1.64336E-05 
53744 1666.78 30.66 0.33 264.94 0.63 258.89 1.02 1.66223E-05 
12993 1009.41 20.98 0.08 77.54 0.32 108.42 0.72 1.86629E-05 
38798 1438.67 27.88 0.88 3752.67 1 4550.73 0.82 1.88571E-05 
99919 2587.2 21.1 0.18 468.84 0.47 666.66 0.70 1.96726E-05 
51838 1635.65 37.38 0.1 226.47 0.35 427.2 0.53 1.98042E-05 
71490 2029.85 20.39 0.31 445.78 0.67 335.8 1.33 2.06707E-05 
43605 1509.79 29.5 0.5 7057.59 0.2 6131.35 1.15 2.10746E-05 
55314 1693.76 20.51 0.27 348.39 0.58 262.53 1.33 2.13348E-05 
111426 2837.36 23.87 0.55 4883.89 0.25 3574.86 1.37 2.16434E-05 
71602 2030.93 32.61 0.91 1846.54 0.91 1008.41 1.83 2.23965E-05 
51175 1630.74 20.65 0.18 210.58 0.46 273.82 0.77 2.34887E-05 
26163 1226.53 21.02 0.58 673.84 0.83 758.01 0.89 2.51304E-05 
12434 995.39 25.11 0.5 284.67 0.23 132.3 2.15 2.56872E-05 
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68411 1962.83 21.97 0.23 533.25 0.56 394.1 1.35 3.01098E-05 
55917 1703.84 33.58 0.23 298.07 0.51 743.94 0.40 3.01684E-05 
67306 1935.81 20.66 0.23 406.53 0.53 416.67 0.98 3.02761E-05 
42188 1483.66 22.59 0.11 642.28 0.36 785.06 0.82 3.03571E-05 
156445 4305.94 28.83 0.86 1787.33 0.96 2673.53 0.67 3.0913E-05 
123634 3148.28 24.16 0.34 301.7 0.64 284.93 1.06 3.383E-05 
98891 2567.13 34.8 0.71 265.4 0.54 135.09 1.96 3.73327E-05 
76053 2108.93 32.93 0.07 108.86 0.3 138.9 0.78 3.80922E-05 
50638 1620.7 22.66 0.31 522.57 0.6 477.87 1.09 3.93812E-05 
75846 2103.96 33.04 0.97 2774.85 0.98 1843.41 1.51 4.15814E-05 
56139 1708.79 30.59 0.71 818.24 0.89 1465.01 0.56 4.27471E-05 
23423 1180.54 25.62 0.08 194.2 0.31 98.15 1.98 4.48896E-05 
32336 1324.57 21.27 0.13 338.38 0.39 354.8 0.95 4.59736E-05 
16976 1084.43 25.23 0.92 1900.2 0.95 2435.82 0.78 4.63093E-05 
43851 1513.44 36.79 0.17 643.87 0.47 495.42 1.30 4.64513E-05 
24958 1209.53 26.15 0.43 509.5 0.69 602.63 0.85 4.64642E-05 
62323 1842.85 24.07 0.1 487.41 0.34 1767.57 0.28 4.65518E-05 
61576 1825.8 31.93 0.32 298.73 0.61 357.37 0.84 5.08976E-05 
93227 2442.07 34.1 0.79 708.3 0.94 855.09 0.83 5.46349E-05 
1495 838.4 35.06 0.16 17.46 0.36 376.78 0.05 5.78108E-05 
38910 1440.56 24.3 0.3 613.88 0.63 406.33 1.51 5.98345E-05 
60248 1796.77 30.92 0.24 243.77 0.52 219.24 1.11 6.25281E-05 
184099 8853.77 21.1 0.15 1491.8 0.42 1670.55 0.89 6.42389E-05 
130044 3336.5 39.38 0.18 1540.1 0.45 1948.69 0.79 6.59767E-05 
102819 2644.22 21.15 0.3 448.42 0.54 706.56 0.63 6.6046E-05 
61405 1821.81 30.17 0.34 460.77 0.63 562.02 0.82 6.71091E-05 
26412 1231.42 21.51 0.14 561.76 0.4 499.34 1.13 6.86967E-05 
108724 2767.32 21.67 0.29 183.13 0.51 322.27 0.57 6.92951E-05 
105105 2687.22 28.99 0.13 64.83 0.36 112.37 0.58 7.16723E-05 
103224 2655.14 22.33 0.15 130.88 0.42 129.08 1.01 7.35479E-05 
106678 2726.25 28.92 0.23 195.1 0.48 200.14 0.97 7.37277E-05 
121940 3098.44 30.06 0.71 485.63 0.89 725.01 0.67 7.37948E-05 
23628 1184.56 26.4 0.18 151.25 0.45 146.39 1.03 7.51756E-05 
115050 2932.32 34.15 0.36 381.56 0.68 305.41 1.25 8.26656E-05 
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125799 3223.42 39.13 0.64 2096.08 0.86 2280.85 0.92 8.30968E-05 
32171 1321.59 28.37 0.97 8865.26 0.96 18773.43 0.47 8.59358E-05 
40091 1449.64 21.86 0.95 5489.33 0.99 7666.71 0.72 8.73287E-05 
130077 3337.45 22.81 0.21 466 0.45 762.99 0.61 8.80379E-05 
49713 1604.73 30.34 0.11 310.87 0.36 186.14 1.67 9.22588E-05 
81457 2216.03 33.83 0.55 216.02 0.73 376.59 0.57 9.53148E-05 
3743 883.41 23.26 0.21 97.1 0.47 132.98 0.73 9.79105E-05 
11282 980.5 22.41 0.26 80.98 0.48 123 0.66 9.83538E-05 
92231 2421 34.86 0.18 115.14 0.44 157.74 0.73 9.88539E-05 
143947 3801.77 33.46 0.43 201.71 0.66 318.74 0.63 9.93604E-05 
52730 1649.71 19.58 0.15 181.54 0.38 316.61 0.57 0.000109001 
62547 1847.89 43.67 0.15 144.9 0.38 350.11 0.41 0.000109001 
40487 1457.6 21.93 0.16 393.55 0.44 238.34 1.65 0.000114019 
61304 1818.83 30.95 0.63 3412.56 0.53 646.82 5.28 0.000114375 
45243 1535.68 22 0.13 725.47 0.4 474.07 1.53 0.000116626 
44464 1521.69 30.53 0.27 156.32 0.54 191.66 0.82 0.000117125 
159259 4404.84 20.67 0.48 803.14 0.7 1234.67 0.65 0.000122825 
98485 2560.12 34.15 0.23 138.35 0.52 111.61 1.24 0.00012327 
62000 1835.84 24.04 0.55 464.05 0.33 226.66 2.05 0.000123449 
48394 1583.7 23.27 0.51 561.63 0.79 543.66 1.03 0.000128732 
82026 2226.99 26.28 0.6 13874.99 0.85 17489.37 0.79 0.000133192 
126982 3256.53 33.03 0.38 1063.61 0.63 1434.24 0.74 0.000135924 
58941 1765.81 31 0.7 1567.7 0.84 2259.23 0.69 0.000138958 
121070 3076.23 19.58 0.45 1096.34 0.75 1084.22 1.01 0.000140442 
111304 2834.19 22.47 0.23 329.83 0.51 199.7 1.65 0.000141054 
71312 2025.87 32.23 0.94 1078.97 0.92 674.42 1.60 0.00014927 
150139 4059.65 20.45 0.13 507.21 0.38 588.82 0.86 0.000159992 
63098 1858.84 24.26 0.19 568.26 0.43 959.79 0.59 0.00016324 
125263 3205.27 19.66 0.67 1121.53 0.84 1531.51 0.73 0.000165029 
37949 1425.59 22.32 0.84 4007.86 0.98 4332.71 0.93 0.000170035 
74987 2089.96 39.52 0.34 200.94 0.57 226.12 0.89 0.000177515 
102725 2642.21 27.7 0.73 374.49 0.88 483.16 0.78 0.000179073 
142080 3734.72 32.5 0.68 213.49 0.77 453.29 0.47 0.000180004 
28850 1270.55 29.38 0.15 159.62 0.39 185.38 0.86 0.000181889 
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57265 1732.77 28.18 0.8 2318.48 0.93 3123.31 0.74 0.000181905 
88093 2336.04 26.66 0.43 261.05 0.21 89.41 2.92 0.000192814 
32022 1319.58 20.89 0.16 208.23 0.41 233.67 0.89 0.000196668 
48580 1588.71 30.15 0.57 657.3 0.79 972.89 0.68 0.000197355 
17830 1097.5 25.41 0.39 352.81 0.17 185.34 1.90 0.000198331 
156878 4321.94 25.2 0.33 3184.53 0.11 966.74 3.29 0.000204459 
23968 1191.52 36.18 0.23 206.01 0.46 401.04 0.51 0.000207062 
68663 1968.88 25.2 0.47 519.19 0.21 557.78 0.93 0.000210243 
181250 7958.47 34.39 0.14 419.43 0.38 412.05 1.02 0.000211993 
106067 2713.23 29.22 0.22 134.31 0.48 149.06 0.90 0.00023196 
117317 2987.35 38.55 0.56 910.56 0.35 295.25 3.08 0.00023425 
136697 3556.59 23.95 0.54 822.31 0.75 1181.43 0.70 0.000239633 
61573 1825.79 20.14 0.73 2839.49 0.94 3352.31 0.85 0.000258194 
124886 3193.38 22.64 0.46 1372.7 0.74 1238.23 1.11 0.000262225 
20700 1140.52 25.38 0.22 147.49 0.46 213.25 0.69 0.000263445 
61340 1819.83 32.13 0.32 839.62 0.13 71.66 11.72 0.000273104 
43226 1503.66 29.68 0.11 90.04 0.31 207.6 0.43 0.000277879 
138143 3593.47 20.2 0.26 536.52 0.52 641.81 0.84 0.000278071 
124735 3187.36 35.62 0.32 284.01 0.53 347.81 0.82 0.000281837 
173077 5213.09 22.43 0.39 329.27 0.67 257.5 1.28 0.000283464 
108021 2754.27 29.68 0.67 306.74 0.79 450.84 0.68 0.000283697 
26670 1235.56 26.65 0.5 849.6 0.57 2832.67 0.30 0.000300503 
100020 2589.06 22.56 0.19 139.26 0.43 159.63 0.87 0.000305354 
159396 4409.89 20 0.48 1279.87 0.72 1793.86 0.71 0.000312092 
49295 1594.73 23.05 0.81 711.82 0.81 330.8 2.15 0.000312635 
65312 1900.87 32 0.18 204.42 0.43 186.61 1.10 0.000324669 
118163 3011.39 29.75 0.89 1143.92 0.94 1539.79 0.74 0.000329751 
97349 2541.19 27.89 0.13 208.47 0.36 112.03 1.86 0.000340482 
31275 1310.59 21.39 0.11 148.01 0.33 121.11 1.22 0.000353299 
139554 3632.74 33.23 0.12 117.32 0.33 129.73 0.90 0.000357574 
65035 1895.07 21.4 0.44 916.62 0.21 565.49 1.62 0.000364447 
148086 3986.65 20.6 0.81 3872.36 0.91 5676.99 0.68 0.000392643 
141672 3718.72 32.48 0.79 334.28 0.81 662.54 0.50 0.000400146 
42594 1491.74 39.83 0.55 381.96 0.71 561.66 0.68 0.000411414 
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72048 2034.99 40.19 0.31 104.8 0.52 148.21 0.71 0.000432848 
123287 3137.41 30.35 0.7 506.04 0.6 342.26 1.48 0.000436572 
44633 1523.84 29.75 0.36 1404.38 0.63 2092.26 0.67 0.00044567 
3052 868.41 23.31 0.4 84.26 0.57 230.43 0.37 0.000452634 
103022 2649.2 34.85 0.14 617.79 0.39 354.22 1.74 0.000454412 
86226 2302.9 43.13 0.31 373.04 0.11 124.32 3.00 0.000460882 
14751 1046.43 27.64 0.17 70.73 0.4 79.7 0.89 0.000468596 
20896 1144.36 35.49 0.11 96.37 0.3 183.47 0.53 0.000487667 
47855 1576.74 19.51 0.43 527.24 0.66 750.62 0.70 0.000490581 
50840 1623.73 24.12 0.89 9939.06 0.99 5733.56 1.73 0.000494355 
175343 5574.25 23.2 0.56 1200.44 0.89 859.43 1.40 0.000505923 
105661 2702.21 38.08 0.7 704.9 0.52 352.49 2.00 0.000512809 
86951 2314.01 33.66 0.58 599.79 0.8 629.88 0.95 0.000518205 
139064 3616.72 33.19 0.57 285.22 0.7 423.62 0.67 0.000523514 
55582 1697.74 30.88 0.87 1006.3 0.94 1338.55 0.75 0.000533651 
136698 3556.6 22.64 0.35 6465.83 0.15 1524.74 4.24 0.00054874 
184206 8917.25 22.55 0.34 452.04 0.61 435.05 1.04 0.00057263 
5661 911.26 34.35 0.89 788.53 0.89 2126.53 0.37 0.000576545 
4976 902.41 20.85 0.76 514.64 0.9 730.44 0.70 0.000581238 
121775 3092.46 31.25 0.64 333.92 0.76 477.73 0.70 0.000581421 
52189 1640.58 23.24 0.87 5589.55 0.98 7511.1 0.74 0.000588492 
7953 940.44 25.14 0.35 128.44 0.15 60.45 2.12 0.000591455 
61945 1834.82 31.09 0.78 6969.39 0.77 1660.16 4.20 0.000596655 
62080 1837.8 30.56 0.14 1953.08 0.35 330.34 5.91 0.000598868 
86677 2308.02 27.34 0.33 200.55 0.56 221.45 0.91 0.000606509 
101786 2627.23 34.99 0.14 527.11 0.39 308.13 1.71 0.000610272 
22835 1173.53 37.49 0.26 186.97 0.46 281.09 0.67 0.000632983 
44592 1523.67 21.97 0.81 6161.47 0.85 7615.86 0.81 0.000640669 
149142 4025.6 20.78 0.24 245.17 0.45 476.52 0.51 0.000652689 
107858 2751.34 29.23 0.48 313.21 0.67 439.04 0.71 0.000653069 
14763 1046.51 25.35 0.13 1498.96 0.34 336.22 4.46 0.000659461 
66197 1916.95 34.19 0.35 161.44 0.6 147.17 1.10 0.000663718 
19655 1126.51 25.52 0.41 152.24 0.16 224.59 0.68 0.000669938 
102371 2639.29 21.42 0.33 297.28 0.54 384.8 0.77 0.000678342 
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79918 2190.99 25.82 0.38 1497.08 0.17 1238.23 1.21 0.000689704 
61332 1819.8 23.36 0.95 5644.1 0.99 6228.52 0.91 0.000695456 
65257 1899.85 24.83 0.43 230.8 0.26 91.2 2.53 0.00069733 
143333 3774.72 22.94 0.36 4239.56 0.18 298.21 14.22 0.000710839 
18833 1113.46 27.3 0.61 285.45 0.73 404.95 0.70 0.00071897 
145479 3871.79 27.57 0.3 292.99 0.56 288.03 1.02 0.000724096 
96716 2525.2 27.74 0.49 548.94 0.63 841.82 0.65 0.000726318 
20659 1139.49 20.97 0.33 1024.77 0.55 1503.22 0.68 0.000733567 
24510 1200.54 24.14 0.55 3745.12 0.66 7839.78 0.48 0.000753934 
25295 1215.45 26.88 0.21 642.19 0.43 956.98 0.67 0.000764996 
56992 1728.77 36.77 0.41 295.3 0.66 266.8 1.11 0.000768981 
117524 2994.38 29.6 0.17 105.93 0.36 207.33 0.51 0.000781908 
89642 2361.11 20.79 0.3 279.82 0.48 531.27 0.53 0.000785407 
92029 2414.63 35.62 0.77 757.09 0.56 584.48 1.30 0.000796642 
58633 1761.69 19.37 0.12 222.09 0.32 280.46 0.79 0.00081529 
16779 1080.5 25.69 0.17 206.52 0.39 191.34 1.08 0.000835479 
85076 2277.01 27.22 0.6 2154.86 0.44 1128.52 1.91 0.000857711 
27350 1247.52 22 0.79 1332.67 0.98 1454.94 0.92 0.000880047 
28669 1267.54 21.17 0.15 374.32 0.38 275.42 1.36 0.000885422 
15296 1060.38 38.31 0.31 85.06 0.51 154.13 0.55 0.000895912 
57537 1737.78 23.73 0.91 5998.4 0.99 5980.02 1.00 0.000900403 
33938 1353.59 21.48 0.68 690.47 0.56 373.67 1.85 0.000913542 
43828 1512.69 26.62 0.45 198.48 0.26 115.21 1.72 0.000944663 
97736 2551.15 34.72 0.67 646.04 0.57 205.4 3.15 0.000966464 
21641 1155.49 20.85 0.28 262.3 0.51 268.38 0.98 0.001006469 
92871 2430.59 35.54 0.73 1003.39 0.51 942.45 1.06 0.00101272 
99251 2574.01 32.81 0.19 86.81 0.42 82.91 1.05 0.001012725 
58355 1754.9 31.26 0.76 6326.81 0.88 8174.64 0.77 0.001027498 
128650 3302.59 23.29 0.34 214.12 0.58 195.96 1.09 0.001058052 
147376 3959.69 19.9 0.19 615.55 0.42 841.72 0.73 0.001070683 
12264 992.42 20.4 0.19 132.87 0.41 132.73 1.00 0.001077376 
92410 2423.09 27.67 0.62 250.12 0.83 286.44 0.87 0.001085023 
29823 1286.42 36.41 0.15 95.57 0.35 99.79 0.96 0.001092108 
146964 3944.71 24.55 0.29 227.59 0.5 248.84 0.91 0.001132718 
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34267 1359.61 23.19 0.19 246.89 0.44 162.86 1.52 0.001150035 
67951 1950.85 35.77 0.78 595.93 0.88 751.65 0.79 0.001167898 
167786 4771.07 20.2 0.4 1011.51 0.6 1341.6 0.75 0.001201307 
33209 1339.6 27.49 0.45 180.64 0.65 214.9 0.84 0.001204047 
20204 1137.51 26.43 0.11 434.52 0.3 150.29 2.89 0.001219826 
112106 2854.36 34.86 0.94 3427.59 1 4566.21 0.75 0.001220385 
121989 3100.42 29.96 0.46 549.99 0.25 439.19 1.25 0.001230127 
97965 2557.17 28.25 0.29 185.08 0.51 152.9 1.21 0.001254961 
84484 2264.94 43.29 0.35 226.09 0.15 173.73 1.30 0.001284535 
15887 1069.47 26.33 0.44 139.18 0.57 232.32 0.60 0.00128533 
61404 1821.82 31.78 0.11 762.89 0.31 243.75 3.13 0.001300509 
14071 1032.5 21.21 0.52 984.59 0.71 1197.89 0.82 0.001312967 
21972 1160.36 35.6 0.89 1675.26 0.93 2434.96 0.69 0.001334528 
68081 1954.01 32.41 0.11 823.79 0.32 172.68 4.77 0.00134757 
152967 4169.93 33.58 0.82 824.03 0.85 1355.53 0.61 0.001360744 
42776 1494.66 30.4 0.49 285.32 0.72 284.56 1.00 0.001361154 
140112 3657.67 40.71 0.7 1392.88 0.83 1698.11 0.82 0.001409881 
912 826.2 33.41 0.16 119 0.35 145.85 0.82 0.001462682 
28385 1262.46 38.23 0.19 476.93 0.43 282.43 1.69 0.001474387 
55315 1693.76 23.48 0.13 174.77 0.34 139.73 1.25 0.001475157 
41665 1470.68 21.08 0.24 148.06 0.48 162.58 0.91 0.001507623 
128525 3298.46 36.05 0.2 158.28 0.4 313.94 0.50 0.001557902 
123750 3152.34 24.55 0.81 867.05 0.67 551.81 1.57 0.001574687 
77236 2138.95 24.24 0.36 282.02 0.19 106.8 2.64 0.001582932 
34339 1361.63 21.99 0.42 883.92 0.73 669.48 1.32 0.001587764 
67217 1933.88 21.62 0.87 1205.87 0.93 601.94 2.00 0.001618074 
46756 1565.69 26.3 0.66 338.54 0.72 153.63 2.20 0.001622515 
32874 1333.42 36.11 0.46 190.41 0.7 204.57 0.93 0.0016362 
21747 1157.54 37.44 0.62 556.29 0.69 1338.8 0.42 0.001640266 
54421 1679.7 22.6 0.28 332.3 0.52 495.09 0.67 0.001644314 
95084 2490.23 24.68 0.62 311.58 0.48 175.73 1.77 0.001659869 
50008 1609.75 30.2 0.35 616.41 0.56 760.58 0.81 0.00166788 
55001 1689.8 27.55 0.18 229.5 0.41 168.39 1.36 0.001683685 
36988 1408.66 39.13 0.47 435.81 0.67 646.42 0.67 0.001694957 
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Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
121413 3080.41 29.98 0.19 267.77 0.41 271.62 0.99 0.00170788 
38752 1438.45 36.76 0.95 6299.03 1 8504.24 0.74 0.001752878 
62256 1841.75 35.66 0.21 112.4 0.43 119.18 0.94 0.001802147 
186609 10999.91 21.37 0.12 3076.39 0.31 3274.45 0.94 0.001816652 
49608 1602.74 28.97 0.54 235.82 0.74 309.63 0.76 0.001823402 
112515 2864.25 20.15 0.19 481.94 0.38 699.29 0.69 0.001837491 
29840 1286.54 29.41 0.15 147.17 0.36 114.15 1.29 0.001847009 
85761 2292.02 27.28 0.89 3613.95 0.99 4405.75 0.82 0.001852538 
19137 1118.49 37.76 0.13 242.56 0.32 265.68 0.91 0.001864894 
22089 1162.54 20.11 0.4 197.65 0.57 300.35 0.66 0.001935978 
140570 3677.77 24.5 0.21 667.59 0.4 927.13 0.72 0.001944946 
78792 2168.97 32.91 0.81 759.53 0.69 522.68 1.45 0.001948639 
32481 1326.57 21.67 0.17 223.38 0.4 165.4 1.35 0.00197206 
34017 1354.64 22.14 0.37 285.98 0.19 162.82 1.76 0.002046432 
74420 2085.93 22.07 0.26 13007.27 0.45 18146.64 0.72 0.002072882 
38879 1439.66 29.82 0.6 1667.3 0.44 238 7.01 0.002098691 
42722 1493.63 21.84 0.27 364.08 0.5 305.57 1.19 0.002124981 
135412 3510.6 40.24 0.42 282.84 0.65 297.9 0.95 0.002145261 
25866 1223.55 27.46 0.27 356.59 0.51 163.06 2.19 0.002146377 
136129 3536.46 20.24 0.18 290.21 0.4 201.71 1.44 0.002183214 
29538 1281.58 27.09 0.26 297.49 0.49 280.07 1.06 0.002236739 
127848 3280.46 22.73 0.19 619.9 0.39 800.21 0.77 0.00231504 
149624 4043.64 20.38 0.63 1121.4 0.74 1763.16 0.64 0.002315639 
20457 1138.59 19.51 0.19 215.46 0.39 173.69 1.24 0.002339778 
146936 3943.83 33.63 0.44 163.49 0.65 196.77 0.83 0.002351086 
128936 3311.48 24.33 0.44 251.08 0.24 189.89 1.32 0.002378275 
45980 1552.5 37.21 0.9 2996.58 0.97 3580.34 0.84 0.002385109 
92841 2430.1 28.33 0.65 329.5 0.84 375.45 0.88 0.002396845 
90470 2380.08 36.51 0.21 216.79 0.43 214.85 1.01 0.002409234 
24113 1194.55 29.2 0.15 103.2 0.33 161.58 0.64 0.002417535 
19871 1130.34 35.39 0.53 558.11 0.64 1079.64 0.52 0.002430554 
26879 1238.56 21.14 0.2 332.92 0.43 197.66 1.68 0.002442083 
85250 2280.94 36.22 0.14 331.51 0.34 283.49 1.17 0.002444939 
53957 1669.69 21.46 0.55 709.99 0.82 528.6 1.34 0.002459676 
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(Da)  
CE Time  
(min)  
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140672 3681.72 32.02 0.2 89.89 0.4 113.44 0.79 0.002463071 
6803 928.37 35.46 0.29 45.84 0.44 127.61 0.36 0.002466511 
70633 2013.89 31.76 0.32 122.15 0.54 109.6 1.11 0.002480881 
76086 2109.92 24.07 0.22 261.69 0.44 219.66 1.19 0.002574392 
131932 3399.35 42.1 0.32 339.73 0.53 421.87 0.81 0.002603657 
15776 1068.45 24.76 0.96 2690.42 0.97 3231.45 0.83 0.002642976 
28103 1257.44 33.92 0.89 4089.39 0.91 5574.78 0.73 0.002662718 
126699 3248.53 30.66 0.77 1355.32 0.77 2192.02 0.62 0.00274941 
60149 1794.8 23.92 0.77 2895.68 0.96 2213.61 1.31 0.002766739 
119292 3035.19 42.02 0.5 792.73 0.68 814.59 0.97 0.002822808 
31524 1312.62 20.01 0.21 461.34 0.45 322.5 1.43 0.002832088 
18077 1101.47 22.27 0.23 241.67 0.46 198.32 1.22 0.002849063 
20750 1141.52 24.51 0.4 216.15 0.55 321.77 0.67 0.002861319 
86354 2305.06 34.91 0.14 276.52 0.34 155.45 1.78 0.002923862 
83081 2243.97 21.16 0.21 275.97 0.43 213.49 1.29 0.00298167 
179035 6650.64 25.54 0.24 389.91 0.47 307.52 1.27 0.003018516 
41471 1467.67 21.29 0.37 433.69 0.57 483.82 0.90 0.003041929 
149760 4044.92 26.37 0.78 3153.32 0.88 3719.27 0.85 0.003044267 
4730 898.32 26.05 0.17 184.1 0.36 335.02 0.55 0.003087261 
114823 2926.3 22.22 0.41 620.73 0.64 490.4 1.27 0.003110471 
37603 1421.49 37.02 0.16 429.84 0.35 392.2 1.10 0.003118877 
70803 2017.88 30.77 0.14 283.92 0.32 265.65 1.07 0.003161555 
13747 1025.46 25.6 0.35 282.35 0.54 288.26 0.98 0.003228503 
18604 1110.39 33.63 0.45 497.7 0.64 631.07 0.79 0.003257642 
113765 2898.31 29.25 0.24 154.8 0.46 140.31 1.10 0.003281968 
139455 3630.44 21.78 0.42 641.21 0.69 473.23 1.35 0.003310055 
85331 2282.02 22.24 0.65 871.79 0.89 790.4 1.10 0.003332737 
130432 3349.42 35.89 0.24 318.83 0.42 340.03 0.94 0.003369281 
76839 2128.98 26.97 0.3 109.36 0.48 137.97 0.79 0.003398132 
16168 1073.32 35.32 0.95 5164.87 0.94 8234.89 0.63 0.003418263 
131548 3384.57 30.83 0.35 137.16 0.17 162.12 0.85 0.003435369 
12380 994.43 25.07 0.29 146.65 0.47 166.2 0.88 0.00347091 
145238 3858.84 25.85 0.53 1344.15 0.73 1406.8 0.96 0.003490185 
28747 1268.57 27.25 0.95 10365.8 0.93 5574.77 1.86 0.003517074 
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(Da)  
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%  MA  %  MA  
141109 3701.74 32.44 0.21 145.46 0.4 219.87 0.66 0.003577469 
61192 1816.9 33.75 0.14 182.11 0.3 256.44 0.71 0.003599324 
127106 3260.49 41.62 0.22 389.53 0.4 569.3 0.68 0.003620083 
3472 875.48 21.94 0.15 107.51 0.33 93.35 1.15 0.003642395 
133345 3439.59 39.22 0.51 309.5 0.32 298.12 1.04 0.003807155 
67612 1942.84 30.96 0.32 124.69 0.52 138.41 0.90 0.003841914 
122623 3114.43 30.29 0.19 153.91 0.35 245.38 0.63 0.003869791 
27742 1251.62 22.53 0.21 365.82 0.42 382.48 0.96 0.003882843 
18029 1100.5 37.04 0.26 99.54 0.42 269.63 0.37 0.004002599 
75248 2096.92 33 0.53 338.55 0.36 231.82 1.46 0.004112489 
46542 1561.45 36.96 0.5 393.2 0.68 481.43 0.82 0.004177997 
20072 1134.58 23.66 0.54 279.26 0.68 438.98 0.64 0.004205651 
47285 1575.75 30.2 0.4 561.74 0.22 439.43 1.28 0.004263712 
50056 1610.87 30.29 0.58 2617.31 0.4 2499.12 1.05 0.004303322 
63427 1865.81 32.98 0.24 118.04 0.46 107.41 1.10 0.00437236 
190524 14109.54 21.93 0.27 1169.35 0.49 956.55 1.22 0.004383509 
85627 2289.04 33.59 0.27 188.66 0.46 200.19 0.94 0.004387083 
70635 2013.91 25.19 0.97 2173.35 0.96 1584.04 1.37 0.004472113 
113439 2889.38 28.65 0.18 142.95 0.36 143.24 1.00 0.00451547 
19791 1128.49 25.65 0.29 203.7 0.46 307.04 0.66 0.004595776 
84300 2261.03 27.15 0.32 1010.59 0.5 1241.27 0.81 0.004615907 
60816 1808.79 23.72 0.4 418.99 0.66 335.75 1.25 0.004768785 
110657 2816.33 28.4 0.18 310.01 0.39 146.46 2.12 0.0048116 
8390 945.42 25.72 0.34 145.95 0.51 186.18 0.78 0.004839887 
79786 2189 26.89 0.64 754.77 0.85 740.66 1.02 0.00484889 
74057 2079 24.68 0.47 386.1 0.72 288.99 1.34 0.004851857 
35979 1390.44 36.95 0.97 27527.64 0.96 36700.74 0.75 0.005040696 
25429 1217.53 35.78 0.26 1889.78 0.43 3416.02 0.55 0.005076705 
57888 1746.59 38.21 0.33 322.71 0.54 370.18 0.87 0.005087859 
59928 1788.84 29.87 0.28 364.58 0.42 763.85 0.48 0.005212313 
56099 1707.81 23.59 0.23 404.84 0.45 221.12 1.83 0.005221556 
97463 2544.13 28.26 0.22 170.37 0.41 199.3 0.85 0.005352599 
59368 1775.79 31.48 0.44 745.55 0.26 711.64 1.05 0.005370367 
29906 1287.59 21.87 0.49 820.27 0.75 774.71 1.06 0.00543093 
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63910 1876.87 22.2 0.9 3082.35 0.99 1652.9 1.86 0.005538579 
136790 3559.71 24.92 0.59 1129.69 0.77 1055 1.07 0.005549831 
100344 2599.19 28.28 0.73 307.71 0.61 237.91 1.29 0.005599519 
127852 3280.56 25.82 0.58 389.96 0.74 526.66 0.74 0.005629617 
160089 4436.08 26.32 0.41 1516.37 0.53 3201.34 0.47 0.005665266 
86071 2298.99 27.08 0.22 883.62 0.4 1119.47 0.79 0.005677983 
59142 1769.71 28.14 0.89 671.18 0.89 483.73 1.39 0.005706788 
24449 1199.58 21.95 0.63 558.52 0.76 629.69 0.89 0.00589006 
73989 2077.96 22.48 0.17 208.55 0.36 191.03 1.09 0.005918759 
91375 2404.01 20.27 0.65 645.16 0.81 795.11 0.81 0.005999377 
152744 4160.92 25.82 0.56 4569.88 0.41 2968.4 1.54 0.006055804 
127237 3261.5 22.19 0.14 325.42 0.31 298.25 1.09 0.00621858 
136789 3559.71 26.52 0.23 398.36 0.43 285.05 1.40 0.00624606 
60126 1793.88 32.37 0.5 772.53 0.78 482.76 1.60 0.006336281 
24308 1196.52 21 0.4 1020.88 0.6 1015.14 1.01 0.006492346 
64899 1892.97 24.56 0.49 538.48 0.64 729.53 0.74 0.006544718 
5184 906.18 34.26 0.33 116.94 0.14 233.04 0.50 0.006599227 
64067 1878.85 32.18 0.15 139.34 0.32 118.22 1.18 0.006666524 
67801 1947.88 31.61 0.45 414.11 0.64 460.56 0.90 0.006709768 
88972 2349.04 27.37 0.22 155.27 0.4 191.3 0.81 0.007193872 
52446 1645.76 20.61 0.21 318.67 0.4 273.87 1.16 0.007208555 
181018 7906.95 19.53 0.18 416.83 0.36 470.1 0.89 0.007361189 
13429 1018.46 24.54 0.28 174.53 0.45 194.11 0.90 0.007476475 
93417 2446.09 28.37 0.33 141.9 0.49 165.94 0.86 0.007546377 
34432 1363.43 36.34 0.98 2453.16 1 2991.62 0.82 0.0076121 
110052 2799.08 25.07 0.98 5294.47 1 4023.2 1.32 0.00778777 
84704 2269.03 39.33 0.62 247.07 0.51 165.12 1.50 0.007811219 
178819 6541.76 20.68 0.22 810.27 0.42 584.36 1.39 0.00783584 
137489 3582.7 19.47 0.69 2756.01 0.59 2064.7 1.33 0.007991576 
35550 1383.64 38.94 0.15 231.09 0.32 166.52 1.39 0.008017769 
37056 1409.58 22.04 0.96 11709.72 1 12667.2 0.92 0.008027411 
50384 1616.73 40.25 0.31 859.74 0.15 1010.84 0.85 0.008076916 
81181 2210.76 37.06 0.24 196.03 0.44 202.99 0.97 0.008142197 
38951 1440.66 39.28 0.4 370.17 0.56 502.54 0.74 0.0084365 
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177971 6236.91 21.07 0.78 2199.25 0.72 1222.24 1.80 0.008442571 
69681 1989.88 32.44 0.68 258.98 0.82 308.19 0.84 0.008442671 
72483 2045.86 34.17 0.29 675.56 0.49 545.34 1.24 0.00849392 
53328 1657.72 22.9 0.19 458.71 0.38 476.97 0.96 0.008548493 
62580 1848.81 30.81 0.42 155.4 0.67 122.08 1.27 0.00860141 
144344 3817.79 33.54 0.14 91.56 0.3 100.37 0.91 0.008631271 
175094 5528.35 28 0.34 428.61 0.19 214.17 2.00 0.008681589 
142141 3737.66 37.21 0.21 141.4 0.39 155.09 0.91 0.009073233 
71171 2023.91 21.48 0.7 482.48 0.66 377.8 1.28 0.00910369 
30524 1296.61 21.69 0.34 657.07 0.19 250.05 2.63 0.00920015 
138813 3605.57 21.19 0.22 261.99 0.39 336.18 0.78 0.009346658 
63517 1867.95 25.15 0.35 812.49 0.2 194.64 4.17 0.009360851 
53393 1658.73 29.94 0.38 479.95 0.51 715.13 0.67 0.009380308 
49334 1595.69 20.15 0.31 569.76 0.53 427.14 1.33 0.009488838 
118053 3007.41 20.95 0.21 605.01 0.4 466.95 1.30 0.009519109 
25099 1212.56 21.2 0.26 186 0.44 184 1.01 0.009553338 
36500 1399.62 28.74 0.18 176.03 0.33 204.07 0.86 0.009695384 
114086 2907.35 35.96 0.71 289.48 0.59 184.38 1.57 0.009826753 
133168 3432.59 32.05 0.88 975.25 0.9 1186 0.82 0.009993548 
77684 2148.02 26.04 0.35 1384.49 0.21 392.59 3.53 0.01001899 
42216 1483.7 20.65 0.43 696.95 0.65 666.35 1.05 0.01008219 
33135 1338.6 23.99 0.83 679.53 0.7 540.09 1.26 0.01010573 
143120 3765.6 20.17 0.2 312.06 0.36 394.62 0.79 0.01011999 
127443 3266.48 30.07 0.14 107.21 0.31 83.22 1.29 0.01021036 
174387 5427.17 22.93 0.21 211.98 0.41 188.96 1.12 0.01024405 
18939 1114.48 24.21 0.39 290.71 0.58 265.93 1.09 0.01033476 
129131 3318.55 30.99 0.27 128.2 0.43 157.66 0.81 0.01069859 
93361 2445.1 28.24 0.21 151.65 0.39 183.1 0.83 0.01089328 
174987 5511.28 22.46 0.19 118.66 0.34 149.9 0.79 0.01090952 
37124 1410.62 19.9 0.2 165.19 0.36 205.91 0.80 0.01099831 
136403 3546.67 26.22 0.19 479.63 0.35 446.44 1.07 0.01119103 
129019 3314.43 20.14 0.36 1212.21 0.53 1428.63 0.85 0.01121206 
34766 1367.64 38.88 0.72 554.73 0.81 732.36 0.76 0.01136759 
77099 2135.96 25.8 0.69 673.94 0.59 429.13 1.57 0.01151054 
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79720 2187.95 39.78 0.94 1515.89 0.97 1750.32 0.87 0.01163086 
20756 1141.54 37.33 0.35 181.85 0.48 333.27 0.55 0.01165872 
54703 1684.71 29.65 0.19 363.61 0.35 413.98 0.88 0.01205231 
32471 1326.56 27.11 0.19 1283.49 0.39 716.64 1.79 0.01209138 
91669 2411.08 26.8 0.31 149.25 0.17 100.42 1.49 0.01210806 
43442 1507.74 40.02 0.93 1880.51 0.94 2799.68 0.67 0.01213974 
76415 2117.93 32.97 0.32 131.04 0.49 143.05 0.92 0.01229273 
89604 2360 33.92 0.17 104.7 0.32 117.46 0.89 0.01247033 
25363 1216.54 24.24 0.82 1060.15 0.77 1895.59 0.56 0.01248304 
132014 3400.58 31.18 0.48 205.96 0.31 213.31 0.97 0.01253784 
131589 3385.55 25.49 0.64 2132.01 0.69 3219.82 0.66 0.01264424 
74065 2078.93 26.67 0.99 8888.59 1 7324.59 1.21 0.01287456 
74273 2081.94 33.66 0.65 647.64 0.73 251.02 2.58 0.01292263 
72033 2034.94 25.45 0.35 885.28 0.23 286.88 3.09 0.01305396 
114438 2917.36 29.04 0.61 1898.3 0.47 1909.22 0.99 0.01305728 
50212 1613.82 23.99 0.57 383.1 0.79 315.83 1.21 0.01345032 
130747 3359.58 31.9 0.79 1087.25 0.9 1219.93 0.89 0.01363732 
50172 1612.76 23.38 0.2 240.43 0.4 162.08 1.48 0.01368028 
127575 3271.49 30.7 0.44 1105.57 0.28 975.34 1.13 0.01386989 
13746 1025.47 25 0.14 253.92 0.3 180.17 1.41 0.0139927 
146624 3927.82 33.6 0.2 128.49 0.33 207.41 0.62 0.01420281 
157882 4352.86 20.17 0.83 5294.82 0.91 6805.13 0.78 0.01436657 
54184 1673.76 40.72 0.39 3263.92 0.24 3109.13 1.05 0.01455398 
82015 2226.97 33.46 0.65 238.19 0.59 158.17 1.51 0.01466353 
81196 2210.95 33.61 0.97 6435.94 1 5197.29 1.24 0.01474302 
84909 2274.04 33.51 0.16 177.25 0.31 167.5 1.06 0.01495276 
36586 1401.66 40.04 0.23 337.11 0.45 130.86 2.58 0.01499299 
46725 1564.72 28.37 0.33 158.99 0.57 109.8 1.45 0.01501347 
127731 3276.24 33.38 0.17 99.07 0.31 139.08 0.71 0.01504871 
40541 1458.63 27.94 0.22 491.76 0.41 290.64 1.69 0.01506282 
67462 1938.88 21.39 0.21 497.65 0.44 125.86 3.95 0.01509124 
54438 1679.95 23.82 0.83 13229.37 0.92 22414.37 0.59 0.01516415 
51865 1635.76 30.34 0.7 1293.45 0.75 1902.28 0.68 0.01519528 
18358 1107.43 25.14 0.33 196.87 0.17 301.02 0.65 0.0154108 
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68117 1954.97 25.36 0.47 564.92 0.32 257.62 2.19 0.01546201 
25053 1211.54 25.82 0.26 286.23 0.46 139.23 2.06 0.0162144 
53866 1668.81 40.47 0.35 456.9 0.53 446.59 1.02 0.01622193 
96879 2529.17 26.99 0.24 141.52 0.43 116.25 1.22 0.01666642 
66054 1915 33.63 0.38 183.16 0.24 124.06 1.48 0.01716301 
30136 1292.39 36.16 0.26 191.03 0.4 242.41 0.79 0.01741059 
120192 3058.38 24.82 0.55 353.37 0.68 410.1 0.86 0.01766189 
17899 1098.52 20.89 0.15 205.48 0.31 129.53 1.59 0.01775929 
3608 879.5 19.88 0.23 135.29 0.36 148.8 0.91 0.0179793 
147000 3945.91 22.03 0.19 565.35 0.31 1053.12 0.54 0.01806868 
55484 1695.73 23.18 0.21 299.38 0.39 284.02 1.05 0.01813328 
69080 1976.88 32.38 0.52 423.33 0.69 429.91 0.98 0.01813836 
38790 1438.66 22.01 0.45 474.69 0.33 257.3 1.84 0.01825064 
99691 2582.17 23.67 0.47 288.62 0.35 155.64 1.85 0.01846494 
46606 1562.69 22.46 0.56 1915.55 0.72 1837.41 1.04 0.01864284 
59149 1769.78 30.98 0.32 364.38 0.19 194.3 1.88 0.01873294 
98720 2565.14 23.74 0.44 424.63 0.34 166.37 2.55 0.01935075 
69882 1993.88 32.19 0.74 327.73 0.74 159.92 2.05 0.0194273 
47402 1576.67 43.3 0.52 3222.02 0.32 4163.23 0.77 0.01946342 
143379 3775.75 25.59 0.84 1306.63 0.84 1593.92 0.82 0.0196265 
140780 3685.83 22.2 0.59 1264.38 0.67 1945.24 0.65 0.01965948 
127354 3264.53 30.66 0.51 273.57 0.69 338.69 0.81 0.01986604 
32343 1324.59 28.7 0.23 417.78 0.39 403.57 1.04 0.02013347 
48417 1584.51 37.5 0.65 548.77 0.82 499.35 1.10 0.02024919 
130803 3361.56 24.24 0.16 202.82 0.31 165.55 1.23 0.02050894 
64493 1886.86 27.3 0.28 173.14 0.46 139.99 1.24 0.02091515 
64869 1892.77 40.25 0.23 1478.73 0.39 1923.99 0.77 0.02098613 
24291 1196.32 36.11 1 27683.09 1 29128.45 0.95 0.02098848 
33238 1340.59 28.4 0.3 158.64 0.49 123.38 1.29 0.02106894 
4845 900.27 43.66 0.28 894.52 0.42 762.13 1.17 0.02115853 
53375 1658.59 21.46 0.18 493.66 0.32 642.58 0.77 0.02122895 
54269 1675.71 29.2 0.23 123.18 0.41 93.02 1.32 0.02150144 
29279 1276.4 35.92 0.97 4428.57 0.98 5469.42 0.81 0.02156291 
26098 1225.32 35.69 0.46 388.09 0.3 484.31 0.80 0.02190198 
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ID  
Polypeptide  Cases  Controls  
R  
P value  
(Unadjusted)  Mass  
(Da)  
CE Time  
(min)  
%  MA  %  MA  
50838 1623.73 29.86 0.36 440.08 0.25 131.78 3.34 0.02194621 
56011 1705.73 40.44 0.46 363.72 0.31 308.21 1.18 0.02198684 
73177 2062.93 26.58 0.87 1114.24 0.92 669.6 1.66 0.02206888 
39607 1447.7 19.47 0.57 751.39 0.71 730.22 1.03 0.02257498 
63143 1859.83 24.41 0.29 608.61 0.5 298.27 2.04 0.02265832 
141019 3697.56 23.7 0.23 279.34 0.38 340.52 0.82 0.02287038 
111564 2841.26 24.54 0.68 1865.83 0.73 772.42 2.42 0.02301055 
138036 3589.68 25.03 0.66 649.35 0.77 927.04 0.70 0.0230354 
28281 1260.56 21.83 0.67 657.29 0.58 494.74 1.33 0.02306255 
3796 884.29 43.81 0.29 124.6 0.41 221.26 0.56 0.0232707 
130482 3350.55 31.02 0.21 124.17 0.36 129.47 0.96 0.02342008 
60975 1812.79 24.14 0.35 287 0.2 544.47 0.53 0.02343743 
50766 1622.7 30.44 0.22 461.79 0.39 208.25 2.22 0.02344096 
48520 1586.74 28.88 0.44 275.83 0.69 191.67 1.44 0.0235215 
97506 2545.12 28.2 0.27 280.79 0.42 276.19 1.02 0.02373503 
117009 2977.37 29.12 0.37 166.36 0.47 256.23 0.65 0.0240074 
40294 1452.66 23.61 0.68 615.56 0.65 397.31 1.55 0.02404588 
19046 1116.53 20.85 0.31 231.33 0.18 277.13 0.83 0.02417943 
37662 1422.6 21.72 0.82 4674.93 0.99 3956.25 1.18 0.02458489 
58759 1761.83 21.65 0.44 406.97 0.33 294.23 1.38 0.02483642 
52320 1643.74 29.53 0.67 382.85 0.88 333.69 1.15 0.02496014 
55450 1694.78 23.59 0.15 195.98 0.3 147.07 1.33 0.02515307 
42867 1496.63 22.34 0.2 467.24 0.39 235.9 1.98 0.02518309 
51328 1632.71 40.15 0.42 665.9 0.27 865.74 0.77 0.02596414 
9930 963.49 21.81 0.34 152.37 0.48 182.26 0.84 0.02600125 
53800 1667.79 40.56 0.57 419.91 0.39 482.85 0.87 0.02603731 
135676 3520.61 30.8 0.36 330.3 0.5 420.67 0.79 0.02603905 
%, percentage of samples, in which the polypeptide could be detected; MA, mean signal amplitude of the polypeptides; CE time, 
capillary electrophoresis migration time.  R was calculated as Σ (ln signal amplitude x frequency/number of participants) in controls 
divided by Σ (ln signal amplitude x frequency/number of participants) in cases.  The polypeptides were ordered by ascending P value.    
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Table S3.   List of polypeptides included in HF1 with available information on amino-acid sequence   
ID Sequence of Polypeptide Protein Name 
Cases  Controls 
 
% MA  % MA R 
8725 GDAGSKGpmV Collagen alpha-1(V) 0.05 1.94  0.63 2.28 0.067 
123106 RDVEEEEEEEGLEEDAELLTELQEVLG Coiled-coil and C2 domain-containing protein 1B 0.05 1.98  0.47 2.63 0.080 
1577 KGDTGPpGP Collagen alpha-1(III) 0.05 1.65  0.47 1.85 0.095 
103493 DEAGSEADHEGTHSTKRGHAKSRPV Fibrinogen alpha 0.05 3.36  0.47 3.29 0.109 
44146 DDFDAHKALEDDE Isoform 1 of Histone-lysine N-methyltransferase MLL2 0.11 1.91  0.58 2.49 0.146 
4845 GGSGAmGSmD 
Immunoglobulin-like and fibronectin type III domain-
containing protein 1 
0.16 1.55 
 
0.63 2.44 0.161 
37610 GPpGpPGSpGEQGPSG Collagen alpha-1(I) 0.11 1.73  0.53 1.87 0.192 
83441 GAVGEKGEPGEAGEpGLpGEGGPpG Collagen alpha-1(V) 0.11 3.45  0.53 3.56 0.201 
74703 KSSSHQDSSRmSSVGDYNT Bone morphogenetic protein 5 0.11 2.64  0.53 2.7 0.203 
101157 GPpGADGQpGAKGEpGDAGAKGDAGpPGPA Collagen alpha-1(I) 0.11 1.97  0.53 1.98 0.207 
103022 FNINNLDNNWLKMHFWFYYA Dermatan-sulfate epimerase-like protein 0.16 2.52  0.68 2.56 0.232 
46091 KGETGDVGQMGppGPP Collagen alpha-1(V) 0.16 2.08  0.53 2.24 0.280 
32022 TYFPHFDLSHG Hemoglobin subunit alpha 0.21 1.99  0.58 2.21 0.326 
82708 GRTGDAGPVGPPGPpGppGpPGPPS Collagen alpha-1(I) 0.32 2.57  0.84 2.68 0.365 
98089 DEAGSEADHEGTHSTKRGHAKSRP Fibrinogen alpha  0.32 2.97  0.84 3 0.377 
61984 DQDKHDDSTDDSDTDK WW domain-binding protein 11 0.53 2.64  1 3.12 0.448 




Collagen alpha-2(I) 0.37 2.26 
 
0.79 2.24 0.472 
39275 DGVGQpGLPGpPGPpG Collagen alpha-1(XVIII) 0.47 2.59  0.79 2.96 0.520 
56493 KGDEGEAGDPGDDNNDI Collagen alpha-1(VI) 0.47 2.56  0.79 2.74 0.556 
41972 EQGLpGAAGQDGPpGP Isoform D preproprotein of collagen alpha-1 (XI) 0.53 2.75  0.84 2.95 0.588 
24168 GPpGPPGPSSNQG Collagen alpha-6(IV) 0.58 2.8  0.84 3.26 0.593 
107858 VSESSIHIIGVSLGAHVGGmVGQLFGGQ Isoform 2 of phospholipase A1 member A 0.63 2.36  0.89 2.69 0.621 
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ID Sequence of Polypeptide Protein Name 
Cases  Controls 
 
% MA  % MA R 
23356 GPpGPpGPSSNQG Collagen alpha-6(IV) 0.58 2.63  0.84 2.9 0.626 
97599 LGSHSQDEEDEDTEYFDAMEDS 101 kDa protein 0.58 2.59  0.89 2.66 0.634 
23697 DDGEAGKpGRpG Collagen alpha-1(I) 0.68 2.8  1 2.88 0.661 
36566 EEEDSSDSSSDSE Isoform 1 of AP-3 complex subunit beta-1 0.58 2.77  0.74 3.27 0.664 
26670 GQDGRpGPpGPpG Collagen alpha-1(I) 0.63 3.02  0.84 3.3 0.686 
58050 GPpGEAGKpGEQGVPGDLG Collagen alpha-1(I) 0.63 2.57  0.84 2.79 0.691 
28005 TYFPHFDLSHG Hemoglobin subunit alpha 0.68 3.08  0.84 3.4 0.733 
69979 KGSpGSDGpKGEKGDPGpEGP Isoform 2C2A' of collagen alpha-2(VI) chain 0.79 2.86  0.95 3.17 0.750 
40737 GPpGPAGNpGpSpNSP Isoform 1 of collagen alpha-1(XXVI) 0.84 3.33  1 3.68 0.760 
65368 WIDAPDDVFYMATEET Metastasis-associated protein MTA1  79 kDa protein 0.79 3.17  0.89 3.61 0.779 
73434 ADGSDLDAVSHGSmDSGHGTH C-myc promoter-binding protein isoform 1 0.84 3.1  1 3.28 0.794 
108574 DmGPpGPQGPpGKDGPPGVKGENGHPGSP Isoform 2 of collagen alpha-1 (XIII)  0.79 3.56  0.89 3.85 0.821 
90344 GKNGDDGEAGKpGRpGERGPpGPQ Collagen alpha-1(I) 0.89 3.12  0.95 3.46 0.845 
36759 PpGPpGFPGDpGPpG Collagen alpha-3(V) 0.89 2.94  0.95 3.18 0.866 
28561 SpGPDGKTGPpGPA Collagen alpha-1(I) 0.89 3.36  0.89 3.79 0.886 
107460 KNGETGPQGPPGPTGPGGDKGDTGPpGpQG Collagen alpha-1(III) 0.95 2.91  1 3.11 0.889 
32171 ApGDRGEpGPpGPA Collagen alpha-1(I) 0.95 4.07  1 4.27 0.905 
39322 GPpGPpGFPGDPGPpG Collagen alpha-3(V) 1 3.2  1 3.49 0.917 
35339 ApGEDGRpGPpGPQ Collagen alpha-1(II) 1 3.36  1 3.53 0.952 
81196 NGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) 1 3.72  1 3.59 1.036 
41601 DGQPGAKGEpGDAGAK Collagen alpha-1(I) 1 3.72  1 3.56 1.045 
62866 SGpQGppGSEGFTGPPGPQG Collagen alpha-2(IV) 1 3.89  1 3.71 1.048 
99021 QQEQLQQQQFQQQQEQLQQQ Zinc finger protein 853 1 3.88  1 3.7 1.049 
79136 AGPpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) 1 3.74  1 3.49 1.072 
50840 DGApGKNGERGGpGGpGP Collagen alpha-1(III) 0.95 4.17  0.95 3.86 1.080 
72533 PpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) 0.95 3.49  0.95 3.21 1.087 
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ID Sequence of Polypeptide Protein Name 
Cases  Controls 
 
% MA  % MA R 
57537 NDGApGKNGERGGpGGpGP Collagen alpha-1(III) 1 4.02  0.95 3.82 1.108 
50212 VGGGEQPPPAPAPRRE Xylosyltransferase 1 0.89 2.7  0.89 2.43 1.111 
60149 GNDGApGKNGERGGpGGpGP Collagen alpha-1(III) 1 3.72  0.95 3.47 1.128 
103198 ERGEAGIpGVpGAKGEDGKDGSpGEpGA Collagen alpha-1(III) 0.89 2.94  0.89 2.47 1.190 
104786 NRGERGSEGSPGHpGQpGppGpPGAPGP Collagen alpha-1(III) 1 3.58  0.89 3.34 1.204 
33135 GAPGPRGRDGEpGT Isoform 1 of collagen alpha-1(II) 1 2.86  0.89 2.65 1.213 
73291 DDKDEEDSPRPRSPPGGPD Zinc finger and BTB domain-containing protein 46 0.84 2.75  0.79 2.37 1.234 
45021 RDGEPGTPGNpGPpGP Isoform 1 of collagen alpha-1(II) 1 2.82  0.89 2.55 1.243 
99475 DDILASPPRLPEPQPYPGAPHHSS Collagen alpha-1(XVIII) 0.95 2.78  0.89 2.38 1.246 
40294 DEPPQSPWDRVK Apolipoprotein A-I 1 2.85  0.84 2.62 1.295 
35424 AMFGPKGFGRGGAE Cysteine-rich protein 1 0.95 2.79  0.79 2.56 1.311 
131294 PGEDGEpGRNGNPGEVGFAGSpGARGFPGAPGLPGL Collagen alpha-2(V) 1 2.87  0.79 2.71 1.341 
111564 ERGEAGIpGVpGAkGEDGKDGSpGEpGANG Collagen alpha-1(III) 0.89 3.21  0.79 2.67 1.354 
104195 NRGERGSEGSPGHPGQPGPpGppGApGP Collagen alpha-1(III) 0.89 2.61  0.74 2.29 1.371 
28747 SpGERGETGPpGP Collagen alpha-1(III) 1 3.44  0.74 3.32 1.400 
44802 GGAGEpGKNGAKGEpGp Isoform 1 of collagen alpha-1(III) 0.79 2.51  0.63 2.1 1.499 
113452 NGEAGSAGPpGppGLRGSpGSRGLPGADGRAG Collagen alpha-2(I) 0.89 2.47  0.58 2.29 1.655 
69681 SNGNpGPpGPSGSpGKDGPpGP Collagen alpha-1(III) 0.84 2.43  0.42 2.51 1.936 
55516 RGSGGGGGGGGQGSTNYGKS Isoform 3 of heterogeneous nuclear ribonucleoprotein A/B 0.79 2.54  0.42 2.39 1.999 
80360 ISVPGPMGPSGPRGLpGPpGApGP Collagen alpha-1(I) 0.68 2.74  0.26 2.73 2.625 
82784 ADGQpGAkGEpGDAGAKGDAGPpGP Collagen alpha-1(III) 0.63 2.28  0.21 2.31 2.961 
ID, polypeptide identifier (SQL number); %, percentage of samples, in which the polypeptide could be detected; MA, mean signal amplitude of the polypeptides. R was calculated as ∑ (ln signal 
amplitude x frequency/number of participants) in controls divided by ∑ (ln signal amplitude x frequency/number of participants) in cases. The polypeptides were ordered by ascending R.   
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Table S4.   List of polypeptides included in HF2 with available information on amino-acid sequence   
ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
97599 LGSHSQDEEDEDTEYFDAMEDS 101 kDa protein 0.38 405.88  0.72 558.72 0.73 0.7200787 
14071 RVAPEEHPV Actin, aortic smooth muscle 0.52 984.59  0.71 1197.89 0.82 0.6296769 
20750 IHEDPGPPPPS ACVR2B Activin receptor type-2B 0.4 216.15  0.55 321.77 0.67 0.6146365 
72343 EAIPMSIPPEVKFNKPFV Alpha-1-antitrypsin 0.43 10352.8  0.03 1273.44 8.13 0.7011054 
87692 EDPQGDAAQKTDTSHHDQDHP Alpha-1-antitrypsin 0.15 273.02  0.58 355.4 0.77 0.7264031 
107198 FFLPDEGKLQHLENELTHDIITK Alpha-1-antitrypsin 0.31 15025.57  0.02 2343.04 6.41 0.6427509 
67632 EAIPMSIPPEVKFNKPF Alpha-1-antitrypsin 0.32 13045.5  0.05 4808.08 2.71 0.6349384 
90840 MIEQNTKSPLFMGKVVNPTQK Alpha-1-antitrypsin 0.43 11705.46  0.08 506.56 23.11 0.6810162 
136698 EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAE Alpha-1-antitrypsin 0.35 6465.83  0.15 1524.74 4.24 0.6088435 
38879 TIDEKGTEAAGAMF Alpha-1-antitrypsin 0.6 1667.3  0.44 238 7.01 0.6206420 
12998 YVVHTNYD Alpha-1-microglobulin 0.14 130.04  0.44 195.64 0.66 0.6536990 
28132 TISEKTSDQIH Antithrombin-III 0.42 1104.88  0.06 529.33 2.09 0.6821854 
40294 DEPPQSPWDRVK Apolipoprotein A-I 0.68 615.56  0.65 397.31 1.55 0.5920493 
29906 LGPHAGDVEGHLS Apolipoprotein A-IV 0.49 820.27  0.75 774.71 1.06 0.6123512 
40487 FHDDGFLAFPGHV Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
0.16 393.55  0.44 238.34 1.65 0.6298895 
53393 DAPGQYGAYFHDDGF Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
0.38 479.95  0.51 715.13 0.67 0.5982674 
44592 AEPGDPRAMSGRSPP Beta-1.3-galactosyltransferase 6 0.81 6161.47  0.85 7615.86 0.81 0.6415816 
106195 LLKNGERIEKVEHSDLSFSKDWS Beta-2-microglobulin 0.34 14019.79  0.04 718.01 19.53 0.6506165 
45243 VEHSDLSFSKDWS Beta-2-microglobulin 0.13 725.47  0.4 474.07 1.53 0.6240434 
74703 KSSSHQDSSRmSSVGDYNT Bone morphogenetic protein 5 0.1 318.89  0.42 493.74 0.65 0.6609269 
24510 KNDQnTSVSHA Bromodomain and WD repeat-
containing protein 3 
0.55 3745.12  0.66 7839.78 0.48 0.6356293 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
74057 SVQPSNHGIYLPSDTQEHA Isoform 1 of Voltage-dependent R-
type calcium channel subunit alpha-
1E 
0.47 386.1  0.72 288.99 1.34 0.6130952 
110657 TTnLEQMMKAGEqGqQqRITFSETG Cation channel sperm-associated 
protein 4 
0.18 310.01  0.39 146.46 2.12 0.5932185 
118597 DGVSGGEGKGGSDGGGSHRKEGEEADAPGVIPG CD99 antigen 0.78 1741.99  0.95 2083.36 0.84 0.6944090 
83081 DGVSGGEGKGGSDGGGSHRKEGEE CD99 antigen 0.21 275.97  0.43 213.49 1.29 0.6022003 
19773 DFDDFNLED CD99 antigen-like protein 2 0.78 1391.02  0.83 2748.43 0.51 0.6856930 
103224 DGVSGGEGKGGSDGGGSHRKEGEEADAPG CD99 CD99 antigen isoform b 
precursor 
0.15 130.88  0.42 129.08 1.01 0.6310587 
68117 SHTSDSDVPSGVTEVVVKL Clusterin 0.47 564.92  0.32 257.62 2.19 0.5889668 
73434 ADGSDLDAVSHGSmDSGHGTH C-myc promoter-binding protein 0.51 1158.94  0.93 2053.5 0.56 0.8159014 
14906 MGPRGPpGPpG Collagen alpha-1(I) chain 0.37 238.08  0.82 738.97 0.32 0.8186650 
78073 AEGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 0.45 904.53  0.88 1576.04 0.57 0.8025085 
23697 DDGEAGKpGRpG Collagen alpha-1(I) chain 0.45 536.63  0.89 884.15 0.61 0.7924107 
2659 DDGEAGKpG Collagen alpha-1(I) chain 0.26 194.46  0.71 568.02 0.34 0.7713648 
30575 SpGSpGPDGKTGPp Collagen alpha-1(I) chain 0.33 1425.18  0.85 1526.54 0.93 0.7771046 
28561 SpGPDGKTGPpGPA Collagen alpha-1(I) chain 0.49 2855.06  0.81 7418.24 0.38 0.7761480 
7408 GRpGPpGPpG Collagen alpha-1(I) chain 0.05 36.97  0.46 169.15 0.22 0.7118410 
2505 SpGEAGRpG Collagen alpha-1(I) chain 0.34 191.41  0.76 383.25 0.50 0.7605761 
17694 ApGDRGEpGpP Collagen alpha-1(I) chain 0.67 3573.1  0.94 5547.8 0.64 0.7645621 
43543 GSpGSpGPDGKTGPPGp Collagen alpha-1(I) chain 0.59 1979.23  0.93 2945.44 0.67 0.7491497 
16773 DRGEpGPpGPA Collagen alpha-1(I) chain 0.09 89  0.46 194.48 0.46 0.6934524 
13342 ApGDKGESGPS Collagen alpha-1(I) chain 0.87 866.5  0.97 1808.79 0.48 0.7371918 
57531 TGSpGSpGPDGKTGPPGpAG Collagen alpha-1(I) chain 0.84 1573.88  0.94 2870.95 0.55 0.7368197 
85020 ADGQPGAKGEpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 0.46 2506.77  0.81 3634.07 0.69 0.7285289 
77763 DGQpGAKGEpGDAGAKGDAGPPGp Collagen alpha-1(I) chain 0.97 3399.7  0.98 1724.29 1.97 0.7332058 
73291 nGDDGEAGKpGRPGERGPpGp Collagen alpha-1(I) chain 0.86 1417.64  0.73 416.98 3.40 0.7308673 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
15561 GPDGKTGPpGPA Collagen alpha-1(I) chain 0.04 61.89  0.34 164.52 0.38 0.6542304 
99808 LTGPIGPPGpAGApGDKGESGPSGPAGPTG Collagen alpha-1(I) chain 0.67 449.89  0.9 700.47 0.64 0.7236395 
82708 GRTGDAGPVGPPGPpGppGpPGPPS Collagen alpha-1(I) chain 0.5 396.97  0.78 760.84 0.52 0.7183780 
61711 SpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain 0.56 877.35  0.28 212.55 4.13 0.6969069 
19284 DGRpGPpGPpGA Collagen alpha-1(I) chain 0.05 270.31  0.35 255.97 1.06 0.6533801 
63209 EGSpGRDGSpGAKGDRGET Collagen alpha-1(I) chain 0.44 1458.34  0.9 1119.04 1.30 0.7149235 
14478 SpGPDGKTGPp Collagen alpha-1(I) chain 0.36 300.27  0.74 286.94 1.05 0.7061543 
88282 GANGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) chain 0.56 594.88  0.84 846.66 0.70 0.7096620 
118224 ESGREGApGAEGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 0.64 4554.03  0.91 7727.54 0.59 0.7112564 
58084 GPpGPpGKNGDDGEAGKpG Collagen alpha-1(I) chain 0.58 950.75  0.9 1120.91 0.85 0.7103529 
72533 PpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) chain 0.94 3157.59  0.91 1786.23 1.77 0.7108844 
90344 GKNGDDGEAGKpGRpGERGPpGPQ Collagen alpha-1(I) chain 0.68 1380.11  0.93 2542.67 0.54 0.7061543 
20862 GLPGPpGPpGPpG Collagen alpha-1(I) chain 0.31 168.72  0.6 380.82 0.44 0.6882440 
73913 GPpGPpGKNGDDGEAGkpGRPG Collagen alpha-1(I) chain 0.27 649.6  0.6 1056.5 0.61 0.6836735 
87365 KNGDDGEAGKpGRpGERGPPGpQ Collagen alpha-1(I) chain 0.09 185.88  0.39 263.28 0.71 0.6502445 
22725 DGAKGDAGApGApG Collagen alpha-1(I) chain 0.17 65.32  0.46 149.11 0.44 0.6629464 
101157 GPpGADGQpGAKGEpGDAGAKGDAGpPGPA Collagen alpha-1(I) chain 0.09 120.1  0.4 95.3 1.26 0.6487032 
55143 PpGEAGKpGEQGVPGDLG Collagen alpha-1(I) chain 0.43 586.61  0.7 907.46 0.65 0.6860119 
38011 PpGKNGDDGEAGKpG Collagen alpha-1(I) chain 0.09 184.4  0.36 193.02 0.96 0.6406781 
122400 ADGQpGAKGEpGDAGAKGDAGpPGPAGPAGPPGpIG Collagen alpha-1(I) chain 0.64 266.08  0.86 354.59 0.75 0.6901042 
77018 DGQPGAKGEpGDAGAKGDAGPPGp Collagen alpha-1(I) chain 0.96 5570.45  0.95 2768.02 2.01 0.6899447 
128435 DRGETGPAGPpGApGAPGAPGPVGpAGKSGDRGETGP Collagen alpha-1(I) chain 0.24 163.97  0.53 343.3 0.48 0.6662415 
58050 GPpGEAGKpGEQGVPGDLG Collagen alpha-1(I) chain 0.45 409.94  0.74 505.2 0.81 0.6803784 
80012 NGDDGEAGkPGRpGERGPpGPQ Collagen alpha-1(I) chain 0.45 641.13  0.74 794.69 0.81 0.6787840 
72896 SGEpGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 0.92 1350.02  0.96 814.06 1.66 0.6837798 
141007 ARGNDGATGAAGPpGPTGPAGppGFpGAVGAKGEAGP
QGPRG 
Collagen alpha-1(I) chain 0.11 184.21  0.39 260.09 0.71 0.6389775 
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39064 SpGENGApGQMGPRG Collagen alpha-1(I) chain 0.55 530.59  0.32 213.77 2.48 0.6650723 
155132 ARGNDGATGAAGpPGPTGPAGPPGFpGAVGAKGEAGp
QGpRGSEGPQG 
Collagen alpha-1(I) chain 0.53 337.4  0.69 749.7 0.45 0.6763393 
91542 LDGAKGDAGPAGPKGEpGSpGENGApG Collagen alpha-1(I) chain 0.68 463.41  0.92 572.79 0.81 0.6800595 
53744 KpGEQGVpGDLGApGPSG Collagen alpha-1(I) chain 0.33 264.94  0.63 258.89 1.02 0.6654974 
99919 PpGKNGDDGEAGKPGRpGERGppGPQ Collagen alpha-1(I) chain 0.18 468.84  0.47 666.66 0.70 0.6476403 
71602 PpGEAGKpGEQGVpGDLGAPGP Collagen alpha-1(I) chain 0.91 1846.54  0.91 1008.41 1.83 0.6761798 
51175 EGSpGRDGSpGAKGDRG Collagen alpha-1(I) chain 0.18 210.58  0.46 273.82 0.77 0.6455145 
68411 PpGPpGKNGDDGEAGKpGRp Collagen alpha-1(I) chain 0.23 533.25  0.56 394.1 1.35 0.6532738 
42188 GPpGKNGDDGEAGKpG Collagen alpha-1(I) chain 0.11 642.28  0.36 785.06 0.82 0.6293048 
50638 PpGPpGKNGDDGEAGKP Collagen alpha-1(I) chain 0.31 522.57  0.6 477.87 1.09 0.6563563 
75846 GPpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) chain 0.97 2774.85  0.98 1843.41 1.51 0.6703869 
56139 pPGEAGKpGEQGVpGDLG Collagen alpha-1(I) chain 0.71 818.24  0.89 1465.01 0.56 0.6694303 
61576 GANGApGNDGAKGDAGApGApG Collagen alpha-1(I) chain 0.32 298.73  0.61 357.37 0.84 0.6549213 
102819 GPpGKNGDDGEAGKPGRpGERGPpGpQ Collagen alpha-1(I) chain 0.3 448.42  0.54 706.56 0.63 0.6485969 
108724 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1(I) chain 0.29 183.13  0.51 322.27 0.57 0.6461522 
105105 KDGEAGAQGPpGPAGPAGERGEQGPAGSpG Collagen alpha-1(I) chain 0.13 64.83  0.36 112.37 0.58 0.6250531 
23628 KpGEQGVpGDLG Collagen alpha-1(I) chain 0.18 151.25  0.45 146.39 1.03 0.6355230 
32171 ApGDRGEpGPpGPA Collagen alpha-1(I) chain 0.97 8865.26  0.96 18773.43 0.47 0.6632653 
130077 GPpGESGREGApGAEGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 0.21 466  0.45 762.99 0.61 0.6363202 
81457 IGPpGPAGApGDKGESGPSGPAGPTG Collagen alpha-1(I) chain 0.55 216.02  0.73 376.59 0.57 0.6583759 
62547 DAGPVGPpGPpGPpGPPGPPS Collagen alpha-1(I) chain 0.15 144.9  0.38 350.11 0.41 0.6245748 
98485 PQGFqGPpGEPGEPGASGPMGpRGPpG Collagen alpha-1(I) chain 0.23 138.35  0.52 111.61 1.24 0.6389243 
82026 GNSGEpGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 0.6 13874.99  0.85 17489.37 0.79 0.6572066 
58941 GPpGEAGKpGEQGVpGDLG Collagen alpha-1(I) chain 0.7 1567.7  0.84 2259.23 0.69 0.6574724 
28850 DGQPGAKGEpGDAG Collagen alpha-1(I) chain 0.15 159.62  0.39 185.38 0.86 0.6213329 
68663 GEpGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 0.47 519.19  0.21 557.78 0.93 0.6301020 
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106067 PpGADGQpGAKGEpGDAGAKGDAGPpGPAGP Collagen alpha-1(I) chain 0.22 134.31  0.48 149.06 0.90 0.6304209 
124886 PpGESGREGAPGAEGSpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain 0.46 1372.7  0.74 1238.23 1.11 0.6467368 
108021 GPpGADGQPGAKGEpGDAGAKGDAGpPGPAGP Collagen alpha-1(I) chain 0.67 306.74  0.79 450.84 0.68 0.6494473 
26670 GQDGRpGPpGPpG Collagen alpha-1(I) chain 0.5 849.6  0.57 2832.67 0.30 0.6425914 
65312 ETGPAGRpGEVGPpGPpGPAG Collagen alpha-1(I) chain 0.18 204.42  0.43 186.61 1.10 0.6217049 
118163 LTGSpGSpGpDGKTGPPGPAGQDGRPGPpGppG Collagen alpha-1(I) chain 0.89 1143.92  0.94 1539.79 0.74 0.6492347 
42594 VGPpGpPGPPGPPGPPS Collagen alpha-1(I) chain 0.55 381.96  0.71 561.66 0.68 0.6430697 
55582 NGApGNDGAKGDAGApGApG Collagen alpha-1(I) chain 0.87 1006.3  0.94 1338.55 0.75 0.6439201 
86677 ADGQpGAKGEpGDAGAKGDAGppGPA Collagen alpha-1(I) chain 0.33 200.55  0.56 221.45 0.91 0.6296769 
107858 RPGApGPAGARGnDGATGAAGPPGPTGpAGpP Collagen alpha-1(I) chain 0.48 313.21  0.67 439.04 0.71 0.6360544 
102371 KEGGKGPRGETGPAGRpGEVGpPGPpGP Collagen alpha-1(I) chain 0.33 297.28  0.54 384.8 0.77 0.6277636 
65257 SGEpGApGSKGDTGAKGEpGP Collagen alpha-1(I) chain 0.43 230.8  0.26 91.2 2.53 0.6195791 
89642 GKNGDDGEAGKPGRpGERGPpGPQ Collagen alpha-1(I) chain 0.3 279.82  0.48 531.27 0.53 0.6224490 
16779 ApGDRGEpGPP Collagen alpha-1(I) chain 0.17 206.52  0.39 191.34 1.08 0.6097470 
85076 ADGqPGAKGEpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 0.6 2154.86  0.44 1128.52 1.91 0.6307398 
27350 DKGETGEQGDRG Collagen alpha-1(I) chain 0.79 1332.67  0.98 1454.94 0.92 0.6381803 
92410 LDGAKGDAGpAGPKGEpGSpGENGApG Collagen alpha-1(I) chain 0.62 250.12  0.83 286.44 0.87 0.6344600 
152967 ERGEQGPAGSpGFQGLpGpAGppGEAGKpGEQGVPGD
LGAPGPSG 
Collagen alpha-1(I) chain 0.82 824.03  0.85 1355.53 0.61 0.6328656 
42776 EpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 0.49 285.32  0.72 284.56 1.00 0.6289328 
55315 PpGPPGkNGDDGEAGKpG Collagen alpha-1(I) chain 0.13 174.77  0.34 139.73 1.25 0.5985863 
67217 GDDGEAGKPGRpGERGPpGP Collagen alpha-1(I) chain 0.87 1205.87  0.93 601.94 2.00 0.6310055 
21747 GPPGPpGppGPPS Collagen alpha-1(I) chain 0.62 556.29  0.69 1338.8 0.42 0.6281888 
50008 TGSpGSpGPDGKTGPpGP Collagen alpha-1(I) chain 0.35 616.41  0.56 760.58 0.81 0.6195791 
29840 DGQpGAKGEpGDAG Collagen alpha-1(I) chain 0.15 147.17  0.36 114.15 1.29 0.5995429 
85761 ADGQpGAKGEpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 0.89 3613.95  0.99 4405.75 0.82 0.6294111 
74420 EGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 0.26 13007.27  0.45 18146.64 0.72 0.6091093 
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29538 SpGSPGPDGKTGPp Collagen alpha-1(I) chain 0.26 297.49  0.49 280.07 1.06 0.6101722 
127848 pPGESGREGApGAEGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 0.19 619.9  0.39 800.21 0.77 0.6013499 
128936 SPGEAGRPGEAGLpGAKGLTGSPGSPGpDGkTGPPGP Collagen alpha-1(I) chain 0.44 251.08  0.24 189.89 1.32 0.6066645 
92841 ADGQPGAKGEpGDAGAKGDAGPpGPAGP Collagen alpha-1(I) chain 0.65 329.5  0.84 375.45 0.88 0.6252126 
114823 ESGREGAPGAEGSpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain 0.41 620.73  0.64 490.4 1.27 0.6159651 
70803 GEpGEpGASGPMGPRGPpGPpG Collagen alpha-1(I) chain 0.14 283.92  0.32 265.65 1.07 0.5907738 
13747 PpGSAGAPGKDG Collagen alpha-1(I) chain 0.35 282.35  0.54 288.26 0.98 0.6113946 
76839 DGKTGpPGPAGQDGRPGPpGppG Collagen alpha-1(I) chain 0.3 109.36  0.48 137.97 0.79 0.6068240 
12380 GPDGKTGPpGP Collagen alpha-1(I) chain 0.29 146.65  0.47 166.2 0.88 0.6057611 
75248 GApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) chain 0.53 338.55  0.36 231.82 1.46 0.6088435 
63427 DAGPAGPKGEpGSpGENGApG Collagen alpha-1(I) chain 0.24 118.04  0.46 107.41 1.10 0.6009779 
70635 NSGEpGApGSKGDTGAKGEpGP Collagen alpha-1(I) chain 0.97 2173.35  0.96 1584.04 1.37 0.6181973 
79786 ADGQPGAKGEPGDAGAKGDAGPpGP Collagen alpha-1(I) chain 0.64 754.77  0.85 740.66 1.02 0.6161777 
63910 DDGEAGKPGRPGERGpPGp Collagen alpha-1(I) chain 0.9 3082.35  0.99 1652.9 1.86 0.6153274 
100344 AGPpGApGApGApGPVGPAGKSGDRGETGP Collagen alpha-1(I) chain 0.73 307.71  0.61 237.91 1.29 0.6132015 
127852 AAGEPGKAGERGVpGppGAVGPAGKDGEAGAQGPpGP Collagen alpha-1(I) chain 0.58 389.96  0.74 526.66 0.74 0.6128295 
73989 GDDGEAGKpGRpGERGPpGPQ Collagen alpha-1(I) chain 0.17 208.55  0.36 191.03 1.09 0.5892326 
88972 GADGQPGAkGEpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 0.22 155.27  0.4 191.3 0.81 0.5915179 
93417 ADGQpGAKGEpGDAGAKGDAGpPGPAGP Collagen alpha-1(I) chain 0.33 141.9  0.49 165.94 0.86 0.5988520 
54703 EpGSpGENGAPGQmGPR Collagen alpha-1(I) chain 0.19 363.61  0.35 413.98 0.88 0.5819515 
43442 VGPpGPpGPpGPPGPPS Collagen alpha-1(I) chain 0.93 1880.51  0.94 2799.68 0.67 0.6042730 
132014 GPpGADGQPGAKGEpGDAGAKGDAGpPGPAGPAGPPG
PIG 
Collagen alpha-1(I) chain 0.48 205.96  0.31 213.31 0.97 0.5917304 
130747 PpGADGQPGAKGEpGDAGAKGDAGPpGPAGPAGPpGPI
G 
Collagen alpha-1(I) chain 0.79 1087.25  0.9 1219.93 0.89 0.6023597 
50172 ApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 0.2 240.43  0.4 162.08 1.48 0.5830145 
82015 NGApGNDGAkGDAGApGApGSQGApG Collagen alpha-1(I) chain 0.65 238.19  0.59 158.17 1.51 0.5987457 
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81196 NGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) chain 0.97 6435.94  1 5197.29 1.24 0.6014031 
84909 GLpGpAGpPGEAGKPGEQGVpGDLG Collagen alpha-1(I) chain 0.16 177.25  0.31 167.5 1.06 0.5754677 
40541 SpGENGApGQmGPRG Collagen alpha-1(I) chain 0.22 491.76  0.41 290.64 1.69 0.5832270 
25053 GPpGEAGKpGEQG Collagen alpha-1(I) chain 0.26 286.23  0.46 139.23 2.06 0.5855655 
96879 GETGPAGRpGEVGPpGPpGPAGEKGSpG Collagen alpha-1(I) chain 0.24 141.52  0.43 116.25 1.22 0.5836522 
63143 NSGEpGApGSKGDTGAKGEp Collagen alpha-1(I) chain 0.29 608.61  0.5 298.27 2.04 0.5834396 
60975 GEpGApGSKGDTGAKGEpGP Collagen alpha-1(I) chain 0.35 287  0.2 544.47 0.53 0.5739796 
97506 GPpGADGQpGAKGEpGDAGAKGDAGpPGP Collagen alpha-1(I) chain 0.27 280.79  0.42 276.19 1.02 0.5794005 
58759 DGEAGKpGRPGERGPpGP Collagen alpha-1(I) chain 0.44 406.97  0.33 294.23 1.38 0.5818452 
5675 DGKTGPpGPA Collagen alpha-1(I) chain 0.29 266.81  0.85 709.73 0.38 0.8384354 
121775 ADGQPGAkGEPGDAGAKGDAGPPGPAGpAGpPGPIG Collagen alpha-1(I) chain 0.64 333.92  0.76 477.73 0.70 0.6411033 
36988 GPPGppGPpGPPGPPS Collagen alpha-1(I) chain 0.47 435.81  0.67 646.42 0.67 0.6251063 
33135 GAPGPRGRDGEpGT Collagen alpha-1(II) 0.83 679.53  0.7 540.09 1.26 0.6062394 
35339 ApGEDGRpGPpGPQ Collagen alpha-1(II) chain 0.95 2232.32  1 3398.04 0.66 0.7731718 
16976 DGpSGAEGpPGp Collagen alpha-1(II) chain 0.92 1900.2  0.95 2435.82 0.78 0.6693240 
93227 GpAGPPGEKGEPGDDGPSGAEGPpGPQ Collagen alpha-1(II) chain 0.79 708.3  0.94 855.09 0.83 0.6675170 
23968 pPGSNGNpGPpGP Collagen alpha-1(II) chain 0.23 206.01  0.46 401.04 0.51 0.6308461 
61192 VGPSGApGEDGRpGPpGPQG Collagen alpha-1(II) chain 0.14 182.11  0.3 256.44 0.71 0.5880102 
32470 SpGGpGSDGKpGPpG Collagen alpha-1(III) chain 0.35 218.46  0.72 362.3 0.60 0.7372449 
30699 DGApGKNGERGGpG Collagen alpha-1(III) chain 0.39 428.35  0.84 409.15 1.05 0.7392645 
18943 SpGERGETGPp Collagen alpha-1(III) chain 0.82 2185.57  0.93 4029.69 0.54 0.7357568 
123969 GERGSpGGpGAAGFpGARGLpGpPGSNGNPGPpGp Collagen alpha-1(III) chain 0.86 1809.86  0.74 981.31 1.84 0.7189626 
107460 KNGETGPQGPPGPTGPGGDKGDTGPpGpQG Collagen alpha-1(III) chain 0.86 919.94  0.96 1398.45 0.66 0.7167304 
1577 KGDTGPpGP Collagen alpha-1(III) chain 0.15 107.18  0.5 205.69 0.52 0.6786777 
18988 DGESGRpGRpG Collagen alpha-1(III) chain 0.07 422.96  0.39 340.14 1.24 0.6550276 
156081 ARGNDGARGSDGQpGppGPPGTAGFPGSpGAKGEVGp
AGSpGSNGApG 
Collagen alpha-1(III) chain 0.46 2355  0.74 3896.07 0.60 0.6979698 
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104786 NRGERGSEGSPGHpGQpGppGpPGAPGP Collagen alpha-1(III) chain 0.97 3608.38  0.91 2259.68 1.60 0.7008397 
110913 LRGGAGpPGPEGGKGAAGpPGppGAAGTPGLQG Collagen alpha-1(III) chain 0.5 386.13  0.75 629.26 0.61 0.6930272 
105352 NRGERGSEGSpGHpGQpGppGPPGAPGp Collagen alpha-1(III) chain 0.97 5094.04  0.96 3271.88 1.56 0.6905825 
98596 ApGPAGSRGApGPQGpRGDKGETGERG Collagen alpha-1(III) chain 0.64 1170.12  0.89 1512.92 0.77 0.6864902 
63135 NpGPPGpSGSpGKDGPpGPAG Collagen alpha-1(III) chain 0.18 299.62  0.47 403 0.74 0.6490221 
38798 GLpGTGGPpGENGKpG Collagen alpha-1(III) chain 0.88 3752.67  1 4550.73 0.82 0.6778274 
156445 ARGNDGARGSDGQpGpPGPpGTAGFpGSpGAKGEVGp
AGSpGSNGApG 
Collagen alpha-1(III) chain 0.86 1787.33  0.96 2673.53 0.67 0.6731505 
106678 KNGETGPQGPPGPTGPGGDKGDTGPpGPQG Collagen alpha-1(III) chain 0.23 195.1  0.48 200.14 0.97 0.6410502 
3743 PpGENGKpG Collagen alpha-1(III) chain 0.21 97.1  0.47 132.98 0.73 0.6367453 
61304 GLpGTGGPpGENGKPGEPGp Collagen alpha-1(III) chain 0.63 3412.56  0.53 646.82 5.28 0.6544430 
62000 ApGApGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.55 464.05  0.33 226.66 2.05 0.6451956 
48394 NDGApGKNGERGGpGGp Collagen alpha-1(III) chain 0.51 561.63  0.79 543.66 1.03 0.6557185 
71312 SEGSpGHpGQpGpPGPPGApGp Collagen alpha-1(III) chain 0.94 1078.97  0.92 674.42 1.60 0.6576318 
88093 ERGSEGSPGHpGQPGpPGPpGApGP Collagen alpha-1(III) chain 0.43 261.05  0.21 89.41 2.92 0.6282951 
156878 LQGLpGTGGppGENGKpGEpGpKGDAGAPGAPGGKGDA
GAPGERGppG 
Collagen alpha-1(III) chain 0.33 3184.53  0.11 966.74 3.29 0.6122449 
61340 GLpGTGGPpGEnGKPGEpGP Collagen alpha-1(III) chain 0.32 839.62  0.13 71.66 11.72 0.6100128 
49295 ApGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.81 711.82  0.81 330.8 2.15 0.6493410 
97349 KNGETGPQGPPGPTGPGGDKGDTGPpGP Collagen alpha-1(III) chain 0.13 208.47  0.36 112.03 1.86 0.6128295 
50840 DGApGKNGERGGpGGpGP Collagen alpha-1(III) chain 0.89 9939.06  0.99 5733.56 1.73 0.6448236 
61945 GLpGTGGPpGENGKpGEPGp Collagen alpha-1(III) chain 0.78 6969.39  0.77 1660.16 4.20 0.6419005 
19655 GGpGSDGKpGPpG Collagen alpha-1(III) chain 0.41 152.24  0.16 224.59 0.68 0.6124575 
61332 ApGAPGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.95 5644.1  0.99 6228.52 0.91 0.6409970 
96716 LRGGAGPpGPEGGKGAAGPpGPpGAAGTpG Collagen alpha-1(III) chain 0.49 548.94  0.63 841.82 0.65 0.6342474 
57537 NDGApGKNGERGGpGGpGP Collagen alpha-1(III) chain 0.91 5998.4  0.99 5980.02 1.00 0.6380208 
97965 KNGETGPQGPpGPTGPGGDKGDTGPPGp Collagen alpha-1(III) chain 0.29 185.08  0.51 152.9 1.21 0.6185162 
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15887 GpGSDGKpGPpG Collagen alpha-1(III) chain 0.44 139.18  0.57 232.32 0.60 0.6254783 
78792 SDGQpGPpGPpGTAGFpGSpGAKG Collagen alpha-1(III) chain 0.81 759.53  0.69 522.68 1.45 0.6277636 
25866 GPGGDKGDTGPpGP Collagen alpha-1(III) chain 0.27 356.59  0.51 163.06 2.19 0.6119260 
70633 AGpPGPPGppGTSGHpGSpGSpG Collagen alpha-1(III) chain 0.32 122.15  0.54 109.6 1.11 0.6134141 
60149 GNDGApGKNGERGGpGGpGP Collagen alpha-1(III) chain 0.77 2895.68  0.96 2213.61 1.31 0.6242560 
85331 ApGHpGPpGPVGPAGKSGDRGESGP Collagen alpha-1(III) chain 0.65 871.79  0.89 790.4 1.10 0.6212798 
28747 SpGERGETGPpGP Collagen alpha-1(III) chain 0.95 10365.8  0.93 5574.77 1.86 0.6213329 
27742 DGVPGKDGPRGPT Collagen alpha-1(III) chain 0.21 365.82  0.42 382.48 0.96 0.5988520 
84300 LQGLpGTGGPpGENGKpGEpGPKG Collagen alpha-1(III) chain 0.32 1010.59  0.5 1241.27 0.81 0.6048044 
13429 SpGGKGEmGPA Collagen alpha-1(III) chain 0.28 174.53  0.45 194.11 0.90 0.5956101 
69681 SNGNpGPpGPSGSpGKDGPpGP Collagen alpha-1(III) chain 0.68 258.98  0.82 308.19 0.84 0.6086841 
71171 GEPGGkGERGApGEKGEGGpPG Collagen alpha-1(III) chain 0.7 482.48  0.66 377.8 1.28 0.6066645 
77099 GDAGApGApGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.69 673.94  0.59 429.13 1.57 0.6026786 
32471 SpGGpGSDGKpGpPG Collagen alpha-1(III) chain 0.19 1283.49  0.39 716.64 1.79 0.5834928 
76415 SNGNpGpPGPSGSPGKDGPpGpAG Collagen alpha-1(III) chain 0.32 131.04  0.49 143.05 0.92 0.5923151 
74065 DAGApGApGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.99 8888.59  1 7324.59 1.21 0.6034226 
127575 NTGApGSpGVSGpKGDAGQpGEKGSPGAQGPPGAPGp Collagen alpha-1(III) chain 0.44 1105.57  0.28 975.34 1.13 0.5879571 
67462 kGNDGApGKNGERGGpGGpGP Collagen alpha-1(III) chain 0.21 497.65  0.44 125.86 3.95 0.5840774 
120192 QNGEPGGKGERGApGEKGEGGppGVAGPpGGSGP Collagen alpha-1(III) chain 0.55 353.37  0.68 410.1 0.86 0.5957696 
69882 SEGSPGHpGQPGpPGpPGApGP Collagen alpha-1(III) chain 0.74 327.73  0.74 159.92 2.05 0.5963542 
32343 TGPGGDKGDTGPpGP Collagen alpha-1(III) chain 0.23 417.78  0.39 403.57 1.04 0.5791348 
54269 GpPGPpGTSGHpGSpGSpG Collagen alpha-1(III) chain 0.23 123.18  0.41 93.02 1.32 0.5791348 
73177 DAGApGAPGGKGDAGApGERGPpG Collagen alpha-1(III) chain 0.87 1114.24  0.92 669.6 1.66 0.5951318 
111564 ERGEAGIpGVpGAkGEDGKDGSpGEpGANG Collagen alpha-1(III) chain 0.68 1865.83  0.73 772.42 2.42 0.5933248 
33209 SpGERGETGPpGPA Collagen alpha-1(III) chain 0.45 180.64  0.65 214.9 0.84 0.6281888 
53800 GPPGFTGPpGPpGPPGPPG Collagen alpha-1(IV) chain 0.57 419.91  0.39 482.85 0.87 0.5857781 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
46091 KGETGDVGQMGppGPP Collagen alpha-1(V) 0.18 150.82  0.51 126.48 1.19 0.6576318 
56493 KGDEGEAGDPGDDNNDI Collagen alpha-1(VI) 0.24 416.31  0.7 672.93 0.62 0.7493622 
54421 ppGDSGppGEKGDPGRP Collagen alpha-1(VII) chain 0.28 332.3  0.52 495.09 0.67 0.6156463 
20756 GPpGPpGPPGPpA Collagen alpha-1(VIII) chain 0.35 181.85  0.48 333.27 0.55 0.5936437 
33973 KGEAGLpGApGSPGQ Collagen alpha-1(XIX) chain 0.68 312.44  0.89 463.05 0.67 0.6986076 
37903 GLPGPpGPpGSFLSN Collagen alpha-1(XVII) chain 0.86 1563.29  0.98 2260.54 0.69 0.6799532 
22835 GPpGPpGPpGPVT Collagen alpha-1(XVII) chain 0.26 186.97  0.46 281.09 0.67 0.6215986 
91342 DDILASPPRLPEPQPYPGAPHH Collagen alpha-1(XVIII) chain 0.45 333.4  0.15 222.75 1.50 0.6684736 
99475 DDILASPPRLPEPQPYPGAPHHSS Collagen alpha-1(XVIII) chain 0.87 691.24  0.9 332.35 2.08 0.7035502 
34766 PpGPpGPpGPPGTPV Collagen alpha-1(XVIII) chain 0.72 554.73  0.81 732.36 0.76 0.6045918 
50838 DpGKDGVGQpGLpGppG Collagen alpha-1(XVIII) chain 0.36 440.08  0.25 131.78 3.34 0.5775935 
48520 QGpRGQpGPPGpPGApG Collagen alpha-1(XXIV) chain 0.44 275.83  0.69 191.67 1.44 0.5901361 
6803 GPpGPYGnPG Collagen alpha-1(XXVII) chain 0.29 45.84  0.44 127.61 0.36 0.6082058 
41434 GpSGPpGPDGNKGEpG Collagen alpha-2(I) chain 0.35 426.47  0.72 472.77 0.90 0.7190689 
80306 NDGPpGRDGQpGHKGERGYpG Collagen alpha-2(I) chain 0.17 374.8  0.5 495.49 0.76 0.6717687 
36769 DGPpGRDGQpGHKG Collagen alpha-2(I) chain 0.19 290.39  0.52 365.14 0.80 0.6745323 
114702 TGEVGAVGpPGFAGEKGpSGEAGTAGPpGTpGP Collagen alpha-2(I) chain 0.26 171.24  0.57 254.69 0.67 0.6767113 
120423 EAGRDGNpGNDGPpGRDGQpGHkGERGYPG Collagen alpha-2(I) chain 0.28 453.18  0.56 815 0.56 0.6762330 
151244 SKGESGNKGEpGSAGPQGPpGPSGEEGKRGPNGEAGS
AGPpGPpG 
Collagen alpha-2(I) chain 0.62 747.28  0.81 1311.78 0.57 0.6813350 
24958 GPpGPDGNKGEpG Collagen alpha-2(I) chain 0.43 509.5  0.69 602.63 0.85 0.6617772 
60248 QGEAGQKGDAGAPGpQGpSG Collagen alpha-2(I) chain 0.24 243.77  0.52 219.24 1.11 0.6454082 
143947 DQGPVGRTGEVGAVGPpGFAGEKGPSGEAGTAGPpGT
pGPQG 
Collagen alpha-2(I) chain 0.43 201.71  0.66 318.74 0.63 0.6538053 
102725 QGPpGPSGEEGKRGPNGEAGSAGPpGPpG Collagen alpha-2(I) chain 0.73 374.49  0.88 483.16 0.78 0.6551871 
139064 DQGPVGRTGEVGAVGPpGFAGEKGPSGEAGTAGpPGT
pGP 
Collagen alpha-2(I) chain 0.57 285.22  0.7 423.62 0.67 0.6406250 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
4976 DpGKNGDKG Collagen alpha-2(I) chain 0.76 514.64  0.9 730.44 0.70 0.6426446 
112515 GRDGNpGNDGPpGRDGQpGHKGERGYpG Collagen alpha-2(I) chain 0.19 481.94  0.38 699.29 0.69 0.6029974 
126699 RTGEVGAVGpPGFAGEKGPSGEAGTAGPPGTpGpQG Collagen alpha-2(I) chain 0.77 1355.32  0.77 2192.02 0.62 0.6237245 
19791 ApGEAGRDGNpG Collagen alpha-2(I) chain 0.29 203.7  0.46 307.04 0.66 0.6021471 
144344 DQGPVGRTGEVGAVGPpGFAGEKGpSGEAGTAGPpGTp
GPQG 
Collagen alpha-2(I) chain 0.14 91.56  0.3 100.37 0.91 0.5794005 
114086 TGEVGAVGPpGFAGEKGPSGEAGTAGPpGTpGP Collagen alpha-2(I) chain 0.71 289.48  0.59 184.38 1.57 0.6051233 
127354 RTGEVGAVGpPGFAGEkGPSGEAGTAGPPGTpGpQG Collagen alpha-2(I) chain 0.51 273.57  0.69 338.69 0.81 0.5936437 
117009 VGEpGPAGSKGESGNKGEPGSAGPqGPpGpSGE Collagen alpha-2(I) chain 0.37 166.36  0.47 256.23 0.65 0.5840774 
55450 GpAGpAGPRGSpGERGEV Collagen alpha-2(I) chain 0.15 195.98  0.3 147.07 1.33 0.5682929 
3052 ApGERGPpG Collagen alpha-2(IV) chain 0.4 84.26  0.57 230.43 0.37 0.6354698 
84484 pGFPGAQGEPGSQGEpGDpGLpGP Collagen alpha-2(IV) chain 0.35 226.09  0.15 173.73 1.30 0.6014031 
20072 PIGQEGAPGRPG Collagen alpha-2(IV) chain 0.54 279.26  0.68 438.98 0.64 0.6153805 
98891 PGSAGPPGSPGPQGSTGPQGIRGqPGDPG Collagen alpha-2(V) chain 0.71 265.4  0.54 135.09 1.96 0.6669855 
121940 LTGNpGVQGPEGKLGPLGApGEDGRpGpPGSIG Collagen alpha-2(V) chain 0.71 485.63  0.89 725.01 0.67 0.6641156 
69979 KGSpGSDGpKGEKGDPGpEGP collagen alpha-2(VI) chain 0.39 720.87  0.86 1396.18 0.52 0.7988946 
43828 SpGSDGPKGEKGDpGP Collagen alpha-2(VI) chain 0.45 198.48  0.26 115.21 1.72 0.6176658 
61405 GpPGEGRAGEpGTAGpTGpP Collagen alpha-2(VIII) chain 0.34 460.77  0.63 562.02 0.82 0.6535927 
61404 GPpGEGRAGEpGTAGpTGpP Collagen alpha-2(VIII) chain 0.11 762.89  0.31 243.75 3.13 0.5954507 
64067 pGFPGTpGLpGmPGHDGAPG Collagen alpha-5(IV) chain 0.15 139.34  0.32 118.22 1.18 0.5841305 
74273 GQDGIPGPAGqKGEPGqpGFGN Collagen alpha-5(IV) chain 0.65 647.64  0.73 251.02 2.58 0.6018282 
18029 pGPPGpPGpPSP Collagen alpha-6(IV) chain 0.26 99.54  0.42 269.63 0.37 0.6005527 
72641 pGppGppGSAGARGEpGpGGRp Collagen. type XII. alpha 1 0.98 4334.17  0.96 1332.88 3.25 0.7834821 
66197 DELPAKDDPDAPLQPVTP Complement C4-A 0.35 161.44  0.6 147.17 1.10 0.6308461 
42866 MIPGGLSEAKPATPE Cystatin-A 0.23 299.77  0.57 229.35 1.31 0.6600234 
103022 FNINNLDNNWLKMHFWFYYA Dermatan-sulfate epimerase-like 
protein 
0.14 617.79  0.39 354.22 1.74 0.6128827 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
38910 DEAGSEADHEGTHS Fibrinogen alpha chain 0.3 613.88  0.63 406.33 1.51 0.6530612 
61573 DEAGSEADHEGTHSTKR Fibrinogen alpha chain 0.73 2839.49  0.94 3352.31 0.85 0.6515731 
53957 DEAGSEADHEGTHSTK Fibrinogen alpha chain 0.55 709.99  0.82 528.6 1.34 0.6239371 
60126 EEAPSLRPAPPPISGGGY Fibrinogen beta chain 0.5 772.53  0.78 482.76 1.60 0.6108099 
60628 LVDFEDNYQFAKYR Ficolin-2 0.34 361  0.78 295.44 1.22 0.7151892 
70456 YLWVGTGASEAEKTGAQEL Gelsolin 0.16 498.15  0.47 654.13 0.76 0.6591199 
32022 TYFPHFDLSHG Hemoglobin subunit alpha 0.16 208.23  0.41 233.67 0.89 0.6230867 
23423 VAHVDDMPNAL Hemoglobin subunit alpha 0.08 194.2  0.31 98.15 1.98 0.6175595 
62080 AVAHVDDMPNALSALSDL Hemoglobin subunit alpha 0.14 1953.08  0.35 330.34 5.91 0.6080995 
77236 SFPTTKTYFPHFDLSHGSA Hemoglobin subunit alpha 0.36 282.02  0.19 106.8 2.64 0.6031037 
41665 DGLAHLDNLKGTFA Hemoglobin subunit beta 0.24 148.06  0.48 162.58 0.91 0.6134141 
19046 PTSRYIHFP Histone-lysine N-methyltransferase 
MLL4 
0.31 231.33  0.18 277.13 0.83 0.5704719 
29685 GSGSGWSSSRGPY Hornerin 0.17 174.58  0.5 235.3 0.74 0.6759141 
47285 IFPPSDEQLKSGTAS Ig kappa chain C region 0.4 561.74  0.22 439.43 1.28 0.5973108 
51865 FIFPPSDEQLKSGTA Ig kappa chain C region 0.7 1293.45  0.75 1902.28 0.68 0.5999150 
15216 TISRLEPED Ig kappa chain V-III region NG9 0.49 1000.53  0.13 477.43 2.10 0.6974915 
4845 GGSGAmGSmD Immunoglobulin-like and fibronectin 
type III domain-containing protein 1 
0.28 894.52  0.42 762.13 1.17 0.5813138 
79918 LSDPEQGVEVTGQYEREKAG Inter-alpha-trypsin inhibitor heavy 
chain H4 
0.38 1497.08  0.17 1238.23 1.21 0.6107568 
39607 DTDRFSSHVGGTLG Inter-alpha-trypsin inhibitor heavy 
chain H4 
0.57 751.39  0.71 730.22 1.03 0.5925808 
44146 DDFDAHKALEDDE Isoform 1 of Histone-lysine N-
methyltransferase MLL2 
0.16 301.07  0.47 429.11 0.70 0.6597577 
54184 PGNPGPpGADGIAGAAGppG Isoform 3 of Collagen alpha-1(XXII) 
chain 
0.39 3263.92  0.24 3109.13 1.05 0.5836522 
59773 LnEDAYmGVVDEATLQ Izumo sperm-egg fusion protein 1 0.33 291.61  0.63 356.09 0.82 0.6704932 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
13746 ATKTVGSDTF Kininogen-1 0.14 253.92  0.3 180.17 1.41 0.5742985 
51838 GSqDGPVSNPSSSnSSQ Liprin-alpha-1 0.1 226.47  0.35 427.2 0.53 0.6301020 
93361 mASDASHALEAALEQMDGIIAGTK Liprin-beta-2 0.21 151.65  0.39 183.1 0.83 0.5857249 
49958 SGDSDDDEPPPLPRL Membrane associated progesterone 
receptor component 1 
0.34 578.89  0.85 739.65 0.78 0.7680697 
44464 GDSDDDEPPPLPRL Membrane associated progesterone 
receptor component 1 
0.27 156.32  0.54 191.66 0.82 0.6420068 
129131 GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAV Metastasis-suppressor  KiSS-1 0.27 128.2  0.43 157.66 0.81 0.5900298 
132057 GRPEAQPPPLSSEHKEPVAGDAVPGPKDGSAPEV Neurosecretory protein VGF 0.4 866.82  0.67 1219.88 0.71 0.6789966 
140780 GRPEAQPPPLSSEHKEPVAGDAVPGPKDGSAPEVRGA Neurosecretory protein VGF 0.59 1264.38  0.67 1945.24 0.65 0.5944940 
33938 NRDGPRQDTQAP Nuclear pore complex protein 
Nup205 
0.68 690.47  0.56 373.67 1.85 0.6341412 
63517 EKETVIIPNEKSLQLQ Osteoglycin 0.35 812.49  0.2 194.64 4.17 0.5848214 
111426 IPVKQADSGSSEEKQLYNKYPDAVAT Osteopontin 0.55 4883.89  0.25 3574.86 1.37 0.6565689 
20700 YNKYPDAVAT Osteopontin 0.22 147.49  0.46 213.25 0.69 0.6280825 
47855 YKRKANDESNEHS Osteopontin 0.43 527.24  0.66 750.62 0.70 0.6377551 
30524 IQNWPHYRSP Peptidoglycan recognition protein 1 0.34 657.07  0.19 250.05 2.63 0.5838648 
73015 ELTETGVEAAAASAISVARTL Plasma protease C1 inhibitor 0.51 433.53  0.23 90.09 4.81 0.6792092 
60816 FAEEKAVADTRDQADGS Polymeric immunoglobulin receptor 0.4 418.99  0.66 335.75 1.25 0.6109162 
33812 DSGSSEEQGGSSRA Polymeric-immunoglobulin  receptor 0.23 217.57  0.63 234.65 0.93 0.7113095 
136697 FAEEKAVADTRDQADGSRASVDSGSSEEQGGSSRA Polymeric-immunoglobulin  receptor 0.54 822.31  0.75 1181.43 0.70 0.6492347 
55917 DHDVGSELPPEGVLGAL ProSAAS 0.23 298.07  0.51 743.94 0.40 0.6503508 
62323 YSQGSKGPGEDFRMATL Prostaglandin-H2  D-isomerase 0.1 487.41  0.34 1767.57 0.28 0.6230867 
63098 YSQGSKGPGEDFRmATL Prostaglandin-H2  D-isomerase 0.19 568.26  0.43 959.79 0.59 0.6283482 
58880 KmHEGDEGPGHHHKPG Protein S100-A9 0.23 354.57  0.54 558.35 0.64 0.6673044 
17830 VIEHIMEDL Protein S100-A9 0.39 352.81  0.17 185.34 1.90 0.6222364 
20204 DTNADKQLSF Protein S100-A9 0.11 434.52  0.3 150.29 2.89 0.5950787 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
3608 KLGHPDTL Protein S100-A9 0.23 135.29  0.36 148.8 0.91 0.5796662 
44679 AHDYFKDTGGDGQD Rab GTPase-activating protein 1 0.58 696.74  0.9 822.72 0.85 0.6905825 
98720 REQGHQKERNQEmEEGGEEEH Retinitis pigmentosa GTPase 
regulator 
0.44 424.63  0.34 166.37 2.55 0.5856186 
60751 SVDETGQmSATAKGRVR Retinol-binding protein 4 0.86 2286.7  0.97 3288.38 0.70 0.6967474 
38790 LQKGNDDHWIVD Retinol-binding protein 4 0.45 474.69  0.33 257.3 1.84 0.5864158 
123750 EGGVNHENGmNRDGGmIPEGGGGNQEPRQQ Rhox homeobox family member 1 0.81 867.05  0.67 551.81 1.57 0.6302083 
125103 SSQGGSLPSEEKGHPQEESEESNVSMASLGE Secretogranin-1 0.16 159.05  0.44 208.66 0.76 0.6462585 
74187 DAHKSEVAHRFKDLGEEN Serum albumin 0.42 809.32  0.71 1202.1 0.67 0.6792092 
17968 DGGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma 
0.62 310.36  0.91 888.01 0.35 0.8322173 
42404 GLSMDGGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma 
0.38 336.54  0.75 655.59 0.51 0.7386267 
49713 TGLSmDGGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma 
0.11 310.87  0.36 186.14 1.67 0.6212266 
48580 TGLSMDGGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma 
0.57 657.3  0.79 972.89 0.68 0.6522109 
43226 GLSmDGGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma 
0.11 90.04  0.31 207.6 0.43 0.6078869 
24660 YLGGSPKGDVDP Sodium/potassium-transporting 
ATPase subunit gamma isoform 2 
0.13 77.91  0.41 159.05 0.49 0.6491815 
56099 REQGVEEHETLLLR TLN1 Talin-1 0.23 404.84  0.45 221.12 1.83 0.5980548 
25363 DAQSGSGQRSQP Ubiquitin-associated protein 2 0.82 1060.15  0.77 1895.59 0.56 0.6034226 
8503 SGSVIDQSR Uromodulin 0.19 140.61  0.48 327.52 0.43 0.6712372 
43605 SVIDQSRVLNLGPI Uromodulin 0.5 7057.59  0.2 6131.35 1.15 0.6506696 
14763 SGSVIDQSRV Uromodulin 0.13 1498.96  0.34 336.22 4.46 0.6056016 
58355 SGSVIDQSRVLNLGPIT Uromodulin 0.76 6326.81  0.88 8174.64 0.77 0.6360544 
11413 VLNLGPITR Uromodulin 0.49 401.63  0.85 1006.41 0.40 0.7746599 
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ID  Sequence of Polypeptide  Protein Name   
Cases   Controls  
R  AUC  
%  MA   %  MA  
65035 SVIDQSRVLNLGPITRK Uromodulin 0.44 916.62  0.21 565.49 1.62 0.6232993 
44633 VIDQSRVLNLGPIT Uromodulin 0.36 1404.38  0.63 2092.26 0.67 0.6359481 
50056 SVIDQSRVLNLGPIT Uromodulin 0.58 2617.31  0.4 2499.12 1.05 0.6105442 
54438 VIDQSRVLNLGPITR Uromodulin 0.83 13229.37  0.92 22414.37 0.59 0.6008716 
59368 FGASAGTGDLSDNHDIIS Vesicular integral-membrane protein 
VIP36 
0.44 745.55  0.26 711.64 1.05 0.5986395 
77684 FGASAGTGDLSDNHDIISMKL Vesicular integral-membrane protein 
VIP36 
0.35 1384.49  0.21 392.59 3.53 0.5846088 
72033 FGASAGTGDLSDNHDIISMK Vesicular integral-membrane protein 
VIP36 
0.35 885.28  0.23 286.88 3.09 0.5825893 
61984 DQDKHDDSTDDSDTDK WW domain-binding protein 11 0.43 884.19  0.85 1510 0.59 0.7767857 
50212 VGGGEQPPPAPAPRRE Xylosyltransferase 1 0.57 383.1  0.79 315.83 1.21 0.6010842 
99691 PEAEAEAEAGAGGEAAAEEGAAGRKARG Zinc finger protein 653 0.47 288.62  0.35 155.64 1.85 0.5874787 
ID, polypeptide identifier (SQL number); %, percentage of samples, in which the polypeptide could be detected; MA, mean signal amplitude of the polypeptides; AUC, area under the curve.   
R was calculated as Σ (ln signal amplitude x frequency/number of participants) in controls divided by Σ (ln signal amplitude x frequency/number of participants) in cases.  The polypeptides were 
ordered by ascending R.   Polypeptides highlighted in red are collagen fragments.  
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Table S5.  Amplitude of 20 shared polypeptides included in CKD273, HF1 and HF2 classifiers   
Polypeptide  CKD273   HF1   HF2  
ID  Case  Control   Case  Control   Case  Control  
1577  167.0 237.3  1.7 1.9  16.1 102.8 
23697  630.2 930.8  2.8    2.9  241.5 786.9 
26670  2430.6 4375.1  3.0 3.3  424.8 1614.6 
28561  5641.3 8205.4  3.4 3.8  1399.0 6008.8 
28747  12225.7 5492.4  3.4 3.3  9847.5 5184.5 
35339  2970.2 4081.1  3.4 3.5  2120.7 3398.0 
50840  6834.4 6183.1  4.2 3.9  8845.8 5676.2 
57537  4911.8 5657.1  4.0 3.8  5458.5 5920.2 
58050  682.2 576.0  2.6 2.8  184.5 373.8 
60149  2047.2 2090.7  3.7 3.5  2229.7 2125.1 
72533  2073.7 2003.5  3.5 3.2  2968.1 1625.5 
79136  4523.0 5039.3  3.7 3.5  5153.1 4211.9 
81196  5000.9 5005.7  3.7 3.6  6242.9 5197.3 
82708  729.3 1169.3  2.6 2.7  198.5 593.5 
90344  1897.5 2434.3  3.1 3.5  938.5 2364.7 
99475  443.7 279.0  2.8 2.4  601.4 299.1 
101157  235.8 162.1  2.0 2.0  10.8 38.1 
104786  2625.4 2540.8  3.6 3.3  3500.1 2056.3 
107460  1642.3 2042.2  2.9 3.1  791.1 1342.5 
143947  428.9 769.6  2.3 2.2  86.7 210.4 
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Table S6.  Host and lifestyle determinants of renal function in stepwise regression models in 797 participants   
Explanatory variables  
Serum creatinine   eGFR (MDRD)   eGFR (CKD-EPI)    
Estimate (95%CI)   Estimate (95%CI)   Estimate (95%CI)   
Women (0,1)  –15.9 (–18.2, –13.6)§   …   …   
Age (+15.7 years)  1.92 (0.79, 3.05)§   …   …   
Smoker (0,1)  –2.80 (–5.07, –0.53)*   2.69 (–0.01, 5.38)   2.55 (–0.15, 5.26)   
Waist-to-hip ratio (+0.08)  –1.33 (–2.62, –0.05)*   …   …   
Mean arterial pressure (+10.7 mm Hg)  1.05 (0.03, 2.07)*   –3.17 (–4.34, –2.00)§   –3.98 (–5.15, –2.80)§   
Blood glucose (+0.78 mmol/L)  …   …   –1.20 (–2.35, –0.05)*   
Log -glutamyltransferase (doubling)  …   1.38 (0.06, 2.72)*   1.33 (–0.01, 2.68)   
Total-to-HDL cholesterol ratio (+1.03)  1.91 (0.88, 2.93)‡   –1.46 (–2.62, –0.31)*   –1.70 (–2.87, –0.54)†   
Log 24-h albuminuria (doubling)   1.87 (0.98, 2.77)§   –1.99 (–3.03, –0.95)‡   –2.45 (–3.51, –1.39)§   
RAAS inhibitor (0,1)  …   –4.12 (–7.13, –1.10)†   –5.68 (–8.73, –2.64)‡   
Vasodilator (0,1)  –5.30 (–9.52, –1.09)*   …   …   
Diuretics (0,1)  8.27 (5.14, 11.4)§   –8.44 (–12.4, –4.50)§   –9.68 (–13.6, –5.73)§   
Covariables considered for entry into the multiple regression models were sex, age and body mass index (only for serum creatinine) and for all renal 
function indices mean arterial pressure, waist-to-hip ratio, smoking, γ-glutamyltransferase (index of alcohol intake), total-to-HDL cholesterol ratio, blood 
glucose, 24–h albuminuria, and use of diuretics, vasodilators (calcium channel blockers and -blockers), and inhibitors of the renin-angiotensin system 
(-blockers, angiotensin-converting-enzyme inhibitors, and angiotensin receptor blockers). For continuous variables, effect sizes are expressed for a 
1–SD increase or a doubling for logarithmically transformed variables. The percentage of variance explained by the whole model was 34.7%, 14.6%, 
and 22.4% for serum creatinine, eGFR (MDRD), and eGFR (CKD-EPI), respectively.  
Significance: * P ≤ 0.05; † P ≤ 0.01; ‡ P ≤ 0.001; and § P ≤ 0.0001.   
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Table S7. Change in eGFR classification during follow-up in 621 
participants  
                  Baseline  
  Stage  1  2  3  4  
MDRD  
Follow-up  
1  34  13  0  0  
2  88  394  11  0  
3  1  48  29  0  
4  0  1  1  1  
CKD-EPI  
Follow-up  
1  82  17  0  0  
2  110  317  6  0  
3  0  53  31  0  
4  0  1  3  1  
Cross-classification of CKD stages according to the eGFR at baseline and follow-up as 
computed by the MDRD and CKD-EPI formulas in 621 participants.   
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Table S8.   Multivariable-adjusted hazard ratios relating endpoints to the urinary proteomic biomarkers in 797 participants   
Endpoint   
(number of events)  
Model  
Hazard ratios (95% Confidence interval)  
CKD273  HF1  HF2  SF  
Cardiovascular events (n = 47)  1  1.15 (0.87, 1.52)  1.29 (0.98, 1.69)*  1.41 (1.07, 1.86)†  1.33 (1.01, 1.74)†  
 2  1.15 (0.87, 1.52)  1.29 (0.98, 1.69)*  1.41 (1.07, 1.86)†  1.33 (1.01, 1.75)†  
 3   1.14 (0.85, 1.52)  1.28 (0.98, 1.69)*  1.40 (1.06, 1.86)†  1.32 (1.01, 1.74)†  
 4  1.14 (0.85, 1.52)  1.29 (0.98, 1.69)*  1.40 (1.06, 1.86)†  1.32 (1.00, 1.74)†  
Cardiac  events (n = 29)  1  1.22 (0.86, 1.73)  1.41 (1.00, 1.99)†  1.32 (0.92, 1.89)  1.37 (0.97, 1.92)  
 2  1.21 (0.85, 1.72)  1.40 (0.99, 1.97)*  1.31 (0.91, 1.89)  1.35 (0.96, 1.90)  
 3  1.24 (0.86, 1.79)  1.41 (1.00, 1.99)†  1.32 (0.91, 1.90)  1.37 (0.97, 1.94)  
 4  1.23 (0.85, 1.78)  1.40 (0.99, 1.97)*  1.32 (0.92, 1.91)  1.36 (0.97, 1.93)  
Hazard ratios, given with 95% confidence interval, express the increase in risk associated with a 1–SD increase in the explanatory variables derived from the urinary 
proteome. SDs were 0.39 for CKD273; 0.92 for HF1; 0.62 for HF2; and 1.0 for SF. The covariables accounted for in model 1 were sex, age, mean arterial pressure, 
body mass index, waist-to-hip ratio, smoking, log -glutamyltransferase (index of alcohol intake), total-to-HDL cholesterol ratio, and blood glucose.  Models 2, 3, and 4 
were additionally adjusted for baseline eGFR according to the MDRD formula, baseline 24–h albuminuria, or both.  
Significance of the hazard ratios: * 0.05 ≤ P ≤ 0.07; † P < 0.05.   





FIGURE S1. Frequency distributions of CKD273, HF1, HF2 and SF at baseline in 797 participants. 
S and K are the coefficients of skewness and kurtosis. The P value is for departure of the actually 
observed distribution (kernel distribution; dotted line) from normality (full line).   
